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The differentiation potential of adult stem cells (ASC) has long been thought to 
be limited to cell lineages present in the organ from which they are derived; however, 
several studies have challenged this notion by demonstrating that some ASC exhibit a 
remarkably high degree of plasticity.  Unlike terminally differentiated somatic cells, the 
less differentiated state of ASC can assume the functional phenotypes and expression 
profiles of cells unique to other tissues. The expansive repertoire of differentiation 
potential exhibited by ASC suggests these cells possess characteristics similar to 
pluripotent cells, including epigenomic regulatory pattern.   Therefore, ASC may be 
better equipped for complete epigenetic reprogramming than terminally differentiated 
cells.   
The objective of Experiment 1 was to analyze bovine adipose-derived adult stem 
cells (ADAS) and fetal fibroblast (BFF) cells for the presence of the pluripotency-
associated genes, Oct-4, Nanog, and Sox-2.  Because the endogenous expression of 
these genes is believed to contribute to reprogramming efficiency, Experiment 2 sought 
to increase Oct-4, Nanog and Sox-2 expression levels in BFF cells through exposure to 
ADAS cell extracts.   
Transcripts for all three pluripotency-associated genes were detected in all BFF 
and ADAS cell samples at every passage analyzed; however, expression was quite low 
and highly variable between cell lines and passage numbers.   Nevertheless, these 
findings support the notion that these cells are less differentiated than other somatic 
cells.  This less differentiated state appears to sufficient for at least the partial 
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reprogramming of BFF cells using ADAS cell extracts in a cell extract-based nuclear 






The extraordinary nature of embryonic stem cells (ESC) lends them the 
remarkable ability to give rise to all the cell types of a mammalian organism, an attribute 
known as pluripotency. The pluripotent state of ESC is contingent upon the expression 
of the genes Oct-4, Nanog and Sox-2, which have also been identified as the key 
transcriptional regulators of pluripotency (Boyer et al., 2005).  Until recently, Oct-4, 
Nanog and Sox-2 were believed to be expressed solely in ESC; however, studies have 
reported the expression of these genes in some sources of adult stem cells (ASC) of 
both the mouse and pig (Kues et al., 2005; Carlin et al., 2006).  Furthermore, these ASC 
as well as several other sources of ASC have been shown to exhibit a surprisingly high 
degree of plasticity.  This remarkable feature allows ASC to cross lineage barriers and 
adopt the expression profiles and functional phenotypes of cells unique to other tissues 
(Herzog et al., 2003).  These findings suggest that ASC possess characteristics similar 
to pluripotent ESC, including an epigenetic regulatory pattern that may be more 
amenable to reprogramming than that of other somatic cells.  Considering the 
abundance and accessibility of adipose tissue, adipose-derived adult stem cells (ADAS) 
cells are an attractive source of stem cells for use in research and biomedical 
applications.   
 In the present study, we first examined cells derived from bovine adipose tissue 
as well as fetal fibroblasts (BFF) for the expression of Oct-4, Nanog and Sox-2.  It has 
been suggested that the genome of less differentiated cells may be more amenable to 
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reprogramming or require less reprogramming following the induction of pluripotency 
either by somatic cell nuclear transfer (SCNT) or another experimental strategy (Rideout 
et al., 2001).  Because of the high degree of plasticity demonstrated by ADAS cells, it is 
likely that these cells have an epigenomic regulatory pattern that is closer to pluripotent 
ESC than terminally differentiated somatic cells (Sun et al., 2009).   
Because the endogenous expression of Oct-4, Nanog and Sox-2 is believed to 
contribute to reprogramming efficiency, we next attempted to increase the expression 
levels of these genes by exposing BFF cells to ADAS cell extracts.  Extract-based 
reprogramming approaches have shown that differentiated cells may be induced to 
transdifferentiate into other differentiated cell types (Collas and Håkelien, 2003) or 
dedifferentiate towards pluripotency (Taranger et al., 2005; Bru et al., 2008).  Because 
the genome of ASC is inherently less differentiated than other somatic cells, exposing 
them to extracts of other ASC may drive them further towards an undifferentiated state.  
Extract-based reprogramming using ASC is a promising and plausible approach 
towards the production of replacement cells for therapeutic purposes, as well as, the 







Stem Cell Basics 
 Stem cells are unlike any cell type, and, of the many different cell types known, 
none are able to mimic the phenomena of stem cells.  ESC possess the ability to 
become any cell type, and, as a result, possess the ability to revolutionize the scientific 
and medical community.  The most popular and perhaps the greatest application of 
stem cells are in regenerative medicine. Regenerative medicine is designed to replace 
or restore cells, organs and tissues that have been damaged or destroyed by disease 
(Hipp and Atala, 2008). Interest in regenerative medicine has heightened throughout the 
years as the demand for organs and tissues in order to satisfy the ever-growing number 
of individuals awaiting transplant far exceeds the supply. Stem cells have the ability to 
create an abundance of cells and tissues to replace those that are damaged or injured.  
In addition, stem cells promise treatment of diseases such as Parkinson's and 
Alzheimer's diseases, as well as healing of spinal cord injury, stroke, burns, heart 
disease, diabetes, osteoarthritis and rheumatoid arthritis.  Yet stem cells’ potentials are 
not limited to medical applications. Studies of stem cells allow scientists to gain a 
greater understanding of the molecular and genetic controls responsible for the 
development of specialized cells from stem cells.  Better understandings of the 
mechanisms regulating this process permit scientists to study malfunctions that can 
occur during this development (Odorico et al., 2001). Consequently, stem cells warrant 
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a great deal of attention, not only from the scientific community, but also from the 
general public.  
Embryonic Stem Cells 
From the first few days of gestation through adulthood, stem cells are present in 
all mammalian species.  Throughout the life cycle, however, stem cells change.  The 
stem cells present in the embryo shortly after fertilization are known as embryonic stem 
cells (ESC) (Evans and Kaufman, 1981; Martin, 1981)whereas the stem cells present in 
an adult are known as adult stem cells (ASC).  In the mouse, nonhuman primates, and 
humans, ESC are derived from the inner cell mass (ICM) of a blastocyst-stage embryo.  
As gastrulation progresses, the stem cells of the ICM will differentiate into the primitive 
ectoderm, which ultimately gives rise to the three germ layers: ectoderm, endoderm, 
and mesoderm.  Under the appropriate culture conditions, these cells can proliferate 
rapidly and, theoretically, remain in an undifferentiated state, capable of generating any 
cell type of the three germ layers, indefinitely (Odorico et al., 2001).   
Adult Stem Cells 
Unlike ESC which are detected only in the ICM of a blastocyst, ASC are found in 
a variety of adult mammalian tissues and organs. ASC primarily function to replenish 
damaged cells within these tissues and organs as a result of normal cellular 
senescence or injury (Odorico et al., 2001).  Researchers have identified many sources 
of ASC, including skin, blood and the brain, although, the most utilized source for these 
cells is bone marrow (Ratajczak et al., 2007).  Although interest in ASC has dramatically 
increased in recent years, their potential in cell-based therapies has long been 
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established.  Since the first procedure in 1956, bone marrow transplants have been 
used to treat patients with certain cancers, such as leukemia and lymphoma, as well as 
individuals suffering from illnesses like Sickle cell anemia and Thalassemia.  
Subsequently, a great deal of research in ASC has focused on these cells, known as 
hematopoietic stem cells (HSC).  Within the bone marrow of an adult animal, HSC 
function to replenish the damaged or dead cells of all the hematopoietic lineages 
throughout its lifetime (Goodell et al., 1996).  HSC function similarly in bone marrow 
transplants, repopulating the reserve of bone marrow and generating healthy new blood 
cells (Hipp and Atala, 2008).  However, the success of bone marrow transplants are 
limited by the number of available donors, which need to have the same human 
leukocyte antigens as the recipient in order to prevent graft rejection (Cairo and 
Wagner, 1997). Despite this limitation, bone marrow transplants have proven to be 
successful in the treatment of several life-threatening illnesses for over 50 years.  The 
identification of HSC in bone marrow prompted researchers to explore other sources as 
potential reservoirs  for HSC, which resulted in the discovery of these cells in placental 
and umbilical cord blood (Broxmeyer, 1989).  Collectively referred to as cord blood, this 
relatively small quantity of blood contains a significantly higher concentration of HSC 
than adult bone marrow and also exceeds the culture life span of adult bone marrow 
(Hows et al., 1992).  Perhaps the greatest attribute of cord blood is that it is far less 
immunogenic than adult peripheral blood, thus enabling its successful application in 
hematopoietic stem cell transplant for both related and unrelated donors (Cairo and 
Wagner, 1997).   
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 Years after the discovery of HSC in bone marrow, researchers identified a non-
hematopoietic population of ASC in the stromal fraction of bone marrow, now known as 
mesenchymal stem cells (MSC).  MSC are often referred to as multipotent adult 
progenitor cells because of their ability to differentiate into many cell lineages, including 
osteoblasts, adipocytes, chondrocytes, myoblasts, and early progenitors of neural cells 
(Sekiya et al., 2002).  This intrinsic property of MSC suggests enormous potential in 
cell-based therapies, fueling research since their original discovery in bone marrow 
stromal cells (Strem et al., 2005).   MSC have since been isolated from a variety of 
tissues, including adipose tissue, which provides a potentially abundant and easily 
accessible source of ASC (Zuk et al., 2001).   
Unique Properties of Stem Cells 
While the source and primary function of stem cells differ between these two cell 
types, both ESC and ASC possess the definite and unique characteristics specific to 
stem cells.  It is these distinctive characteristics that make them especially valuable in 
clinical application.  One unique aspect of stem cells is their remarkable potential to 
develop into many different cell types.  When a stem cell divides, it can either become 
another stem cell or it can become another type of cell with a more specialized function.  
The ability of stem cells to take on the form of different cell types is called differentiation 
(Odorico et al., 2001). ESC are capable of forming all cell types, but most ASC can only 
differentiate into the cell type of the tissue from which they are found.  This is why ASC 
are often referred to as tissue-specific cells.   However, there are certain kinds of ASC 
that are capable of differentiating into cells of a variety of tissue.   For example, bone 
marrow is one of the most common sources of ASC.  This is because it is a source of 
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different types of stem cells, therefore, capable of developing into a variety of 
differentiated cell types.    Specifically, bone marrow stromal cells are capable of 
generating cells that can develop into bone, cartilage, fat, and fibrous connective tissue 
(Sekiya et al., 2002).    
Unlike ASC, ESC are identified in only one location, and their differentiation 
potential is not limited in regards to tissue type.  Instead, ESC are pluripotent.  A 
pluripotent stem cell is able to develop into any type of cell of the endoderm, ectoderm, 
or mesoderm, but it cannot differentiate into embryonic membranes.  Because ESC 
cannot give rise to extra-embryonic membranes, they are not totipotent and labeling 
them as such is incorrect.   Alternatively, the zygote is totipotent, and it remains 
totipotent through the morula stage. Following the morula stage, cells enter the 
blastocyst stage, and it is at this time that the trophoblast cells develop and migrate to 
the periphery of the cell to form what will be the placenta.  Encompassed inside the 
trophoblast is the inner cell mass that will form the fetus. Cells of the inner cell mass are 
pluripotent, and these are the cells used for research and medical applications.  The 
ability of stem cells to undergo differentiation is one of the characteristics that make 
them unlike any other cell type, therefore, capturing the interests of many. 
  Stem cells are able to differentiate into various cell types because they are 
unspecialized. Stem cells, unlike other cells in the body, do not perform a specialized 
function because they lack any tissue-specific structures.  Despite ASC being found 
with other tissue-specific cells, they are less differentiated than the surrounding somatic 
cells, and retain the ability to renew and differentiate to yield the major specialized cell 
types of the tissue (Sekiya et al., 2002).  Because stem cells are unspecialized they 
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cannot carry out the critical functions of heart cells or neural cells; however, these 
unspecialized stem cells can give rise to specialized cells like heart cells and neural 
cells. It is this feature that gives stem cells their great potential.  
In addition to the properties mentioned, stem cells are also characterized by 
having the ability to divide and renew themselves for extended periods of time.  As 
previously discussed, stem cells can differentiate into a number of other cell types, yet 
they can also replicate many times to create more stem cells, remaining unspecialized.  
If the cells continue to replicate for an extended period of time, it is known as 
proliferation.   Proliferation of a stem cell line in a laboratory setting for a few months 
can result in millions of stem cells (Odorico et al., 2001), thus, ensuring their ability of 
long-term renewal. 
The Problem with Stem Cells  
Despite the promise of stem cells, there are many obstacles to overcome before 
they can fully express their potential in medical applications.   Since its emergence, 
immune rejection has plagued transplant and gene therapy, limiting its success in some 
patients.  Immune rejection is also a potential complication of stem cell therapy, 
particularly with ESC, and, while immunosuppressive drugs limit the possibility of 
rejection, their use has been associated with numerous complications, including wound 
healing, opportunistic infections, drug-related toxicities, skin malignancies, and post-
transplant lymphoproliferative disorders (Odorico et al., 2001).   
Furthermore, undifferentiated stem cells have been shown to produce tumors in 
animals, reinforcing this as a potential consequence of stem cell therapy (Donovan and 
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Gearhart, 2001).   Technical hurdles, such as the establishment of optimal ESC culture 
conditions are another obstacle yet to be overcome. For ESC to be an effective tool in 
regenerative medicine, they must be produced in large quantities and be able to 
differentiate into a homologous cell population (Donovan and Gearhart, 2001). While 
promising advances in stem cell research frequently emerge, not all of stem cells’ 
impediments can be resolved by science.  Unfortunately, the remarkable potentials of 
stem cells are often overshadowed by the controversy surrounding them, particularly 
ESC.  All ESC are truly pluripotent, exceeding the inherent differentiation capabilities of 
ASC, but, because ESC are derived from the inner cell mass of a blastocyst, there are 
ethical concerns over the use and subsequent disposal of human embryos.  In fact, 
government funding of ESC research has been limited for the past 8 years due to these 
moral concerns.  However, ESC research regained momentum on March 9, 2009, when 
President Obama removed these limitations in the hopes of potentiating the capabilities 
of stem cells in medical applications.  While this barrier has been removed, research in 
ASC and stem cell alternatives have not been neglected and continue to be 
frontrunners in scientific research. 
  ASC are present in many organs and tissues, including mesenchyme, adipose 
tissue, and endothelial tissue (Gimble et al., 2007), therefore they are an attractive and 
successful option for the treatment of many diseases. Hematopoietic stem cell 
transplants have been successfully used to treat many patients with life-threatening 
diseases, such as leukemia for years.  From 1988 to 1997, there were an estimated 500 
related and unrelated hematopoietic stem cell transplants using umbilical cord blood 
(Cairo and Wagner, 1997).  ASC have had an unprecedented impact on cell-based 
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therapies; however, despite the proven capabilities of ASC in regenerative medicine, 
ASC are multipotent, which limits their differentiation capabilities and, ultimately, their 
therapy potentials to their tissue of origin. The promise of a treatment for diseases such 
Type I diabetes, in which pancreatic islet cells have been destroyed, or Parkinson’s 
disease, which results from the destruction of dopaminergic neurons truly lies within the 
use of ESC (Odorico et al., 2001).  In fact, insulin- producing pancreatic islet-like cells 
have been generated from ESC, (Murtaugh and Melton, 2003), and studies in the rat 
have proven that dopamine neurons, derived from ESC, develop functional synapses 
and display electrophysiologic properties characteristic of midbrain neurons following 
transplantation, providing a realistic approach to the treatment of Parkinson’s disease 
(Kim et al., 2002).  
  In addition, there are typically only a small number of stem cells within an organ 
or tissue, and research has shown that it is difficult to produce large numbers of these 
cells once in culture because ASC lose their proliferative and differentiation capabilities 
as cell cultures are expanded (Sekiya et al., 2002), further limiting their use in medicine.  
Undoubtedly, ASC have made immense contributions to the success of cell- based 
therapy, proving to be effective in the treatment of several diseases; however, the 
multipotent nature of ASC limits the variety of cell types that can be produced, rendering 
them inherently incapable of producing the certain cell types needed for the treatment of 





Pluripotency in Embryonic Stem Cells 
The ability of ESC to basically become any cell type is the foundation of their 
potentials, verifying pluripotency as their most notable and heralded property.  Despite 
the early stage of development and relatively small number of cells, the cells of the ICM 
express their pluripotent potential by giving rise to the 3 germ layers: ectoderm, 
endoderm and mesoderm, which will eventually give rise to all the organs and tissues of 
the body (Odorico et al., 2001).  The proper development and progression of the 
preimplantation embryo to the implanting blastocyst is dependent upon carefully 
regulated molecular and cellular events within the embryo (Ovitt and Schöler, 1998) 
Proper development of the early stage embryo relies upon a precise series of 
events controlled by the expression of specific genes.  Conversely, accurate gene 
expression is dependent upon transcriptional activity, which is responsible for regulating 
biological processes throughout life.  In recent years, interest and subsequent research 
in stem cells has escalated, resulting in several advances in stem cell biology.   Many of 
these advances are due to the identification and characterization of ESC transcription 
factors, especially those responsible for regulating pluripotency.  Researchers have 
identified Oct-4, Sox-2, Nanog, Klf4 and Myc as the key pluripotency-regulating 
transcription factors in ESC (Takahashi and Yamanaka, 2006).   
Oct-4 Expression in Embryonic Stem Cells 
Octamer 4, designated as Oct-4, is a homeodomain transcription factor of the 
POU family essential for the expression of pluripotency in ESC (Ovitt and Schöler, 
1998). Oct-4 is found not only in ESC, but in primordial germ cells (PGC) and 
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unfertilized oocytes (Schöler et al., 1990), as well as embryonal carcinoma cells (Ovitt 
and Schöler, 1998).  Originally, Oct-4 is present as maternal RNA and protein in 
unfertilized oocytes.  As the case with most maternal RNAs, however, maternal Oct-4 
RNA and protein levels decrease upon fertilization, rendering it undetectable past the 2-
cell stage of embryogenesis.  It is at this time, the 4 to 8 cell stage, that zygotic Oct-4 
gene expression is activated in the mouse embryo (Schöler et al., 1990).  All 
blastomeres at this early-cleavage stage express Oct-4 uniformly; however, the 
expression of Oct-4 becomes restricted as development progresses.  Those cells of the 
morula destined to form the placenta, migrate to the periphery of the developing embryo 
and differentiate into the cells of the trophectoderm (Kehler et al., 2004).  Consequently, 
Oct-4 is down-regulated in these peripheral cells and is expressed solely by the cells of 
the ICM.  As embryonic development continues, Oct-4 is restricted once again as the 
cells of the ICM differentiate into the hypoblast and epiblast.   The expression of Oct-4 is 
maintained in the cells of the epiblast, which are responsible for the formation of the 3 
germ layers during gastrulation; however, Oct-4 expression is undetectable in the cells 
of the hypoblast as they differentiate (Kehler et al., 2004).  During gastrulation, Oct-4 
expression in the epiblast is gradually reduced until it is confined solely to primordial 
germ cells (PGC) (Schöler, 1990).  As the preimplantation embryo progresses through 
the stages of embryogenesis, cells differentiate, and, as a result, Oct-4 expression is 





Nanog Expression in Embryonic Stem Cells 
 At each ESC division, cell fate is determined by the expression, or lack thereof, 
of regulatory intrinsic factors (Chambers et al., 2003).  The fate of the cells of the 
preimplantion embryo is first determined at the morula stage, where cells that retain the 
expression of Oct-4 are sequestered to the ICM, and those that do not express Oct-4 
differentiate into the trophectoderm (Kehler et al., 2004).  After the formation of the 
blastocyst, the cells of the ICM rapidly proliferate, selectively differentiate and 
reorganize as a pluripotent cell population under the direction of another transcription 
factor, known as Nanog (Mitsui et al., 2003).   Like Oct-4, Nanog is a homeobox-
containing transcription factor that plays an essential role in regulating early embryonic 
development and maintaining pluripotency in the cells of the ICM (Chambers et al., 
2003).  Both Oct-4 and Nanog function in the same restricted expression mechanism to 
specify pluripotency in ESC, but their roles in this process are unique (Boyer et al., 
2005).  Nanog expression levels are highest between the late morula and mid 
blastocyst stage of embryogenesis, when the pluripotent cells of the ICM divide a 
second time into the epiblast and hypoblast.  A pluripotent cell population is maintained 
in the epiblast by restricting Nanog expression to these cells (Chambers et al., 2003).  
Disruption of this expressive pattern causes ESC to improperly differentiate into 
hypoblast, and deletion of the Nanog gene curtails pluripotency in both the ICM and 
ESC (Chambers et al., 2003; Mitsui et al., 2003).  Therefore, Nanog plays an 
indispensible role in early embryonic development and in the maintenance of 




Sox-2 Expression in Embryonic Stem Cells 
 In addition to Oct-4 and Nanog, Sox-2 has also been identified to play an 
essential role in early embryonic development and the propagation of pluripotency in 
ESC.  Sox-2 is a member of the Sex Determining Region-Y (SRY)-High Mobility Group 
(HMG) box gene family that acts to maintain the developmental potential of ESC 
(Avilion et al., 2003).  Sox-2  is not only expressed in the ICM, epiblast, and germ cells, 
but it is also present in multipotent cells of the extraembryonic ectoderm (Avilion et al., 
2003).  In the mouse embryo, Sox-2 RNA is distinctively present in the ICM of the 
blastocyst, although some cells of the morula stage embryo express Sox-2.   As Nanog 
directs the division of the ICM into the epiblast and hypoblast, Sox-2 is confined to the 
epiblast, where it continues to be expressed until the mid-late streak stage of 
development.  At this time, Sox-2 expression is confined to the anterior portion of the 
primitive streak, specifically the presumptive neuroectoderm, however, it is the 
expression of Sox-2 at a second location that results in its presence in the 
extraembryonic ectoderm.  The extraembryonic ectoderm forms from the polar 
trophectoderm, the portion of the trophectoderm in direct contact with the ICM, and 
gives rise to the various cell types of the placenta and other structures such as the 
chorion.  By day 9.5 postcoitum, Sox-2 is present throughout the mouse brain, neural 
tube, sensory placodes, branchial arches, gut endoderm, and both male and female 
germ cells (Avilion et al., 2003). Furthermore, ESC that are Sox-2 deficient improperly 
differentiate into trophectoderm-like cells, confirming that like Oct-4 and Nanog, Sox-2 is 
an indispensible factor in the maintenance of ESC pluripotency (Masui et al., 2007).   
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Transcriptional Regulation of Oct-4, Nanog and Sox-2 in Embryonic 
Stem Cells 
Oct-4, Nanog and Sox-2 are the key components of the transcriptional regulatory 
circuitry that governs pluripotency in ESC. This intricate circuitry involves the up and 
down regulation of Oct-4, Nanog, and Sox-2 target genes, which ensure proper early 
embryonic development and the reproduction of undifferentiated ESC. The 
transcriptional regulation circuitry responsible for ESC identity is dependent upon the 
precise action of a series of complex molecular and cellular mechanisms.  The exact 
mechanism responsible for regulating ESC self-renewal and pluripotency is still largely 
unknown, perhaps because the function of the molecular and cellular machinery 
responsible for these properties is not fully understood  (Loh et al., 2006).  
Nevertheless, a great deal of research has recently focused on providing a greater 
understanding of the mechanisms involved in maintaining the properties of ESC.   
In 1981, Evans and Kaufman demonstrated that mouse ESC could be expanded 
and maintained in culture by co-culturing them with mitotically inactive fibroblast cells; 
however, it was not until 1988 that the factor responsible for promoting self-renewal 
while inhibiting differentiation was identified (Smith et al., 1988; Williams et al., 1988).  
Leukemia Inhibitory Factor (LIF), a member of the IL-6 cytokine family, promotes 
pluripotency in ESC by activating STAT3.  LIF mediates the activation of STAT3 through 
a receptor complex composed of a low affinity LIF receptor, known as LIFRβ, and 
gp130.  The binding of LIF to the LIFRβ-gp130 heterodimer activates STAT3 in ESC 
through a process of tyrosine phosphorylation, dimerisation and translocation of the 
dimerized STAT3 signaling molecule to the cell nucleus, which initiates the transcription 
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of STAT3.  Activation of this transcription factor is absolutely essential for the self-
renewal of mouse ESC (Matsuda et al., 1999); however, neither LIF nor STAT3 is 
directly responsible for maintaining the pluripotent state of ESC (Mitsui et al., 2003).   
Instead, the LIF receptor, gp130, mediates the activation of STAT3, which regulates 
gene expression by interacting with Oct-4.  Similar cell differentiation patterns result 
when either Oct-4 is overexpressed or STAT3 is inactivated, illustrating an intersection 
between these two transcription factors (Mitsui et al., 2003).   Alternatively, Nanog is 
capable of sustaining self-renewal of ESC in the absence of STAT3 activation; 
therefore, its function is independent of LIF/STAT3 pathway (Chambers et al., 2003).  
Chambers et al (2003) also showed that an overexpression of Nanog is capable of 
promoting ESC self-renewal in the absence of STAT3 activation, but maximum self-
renewal efficiency requires both Nanog and STAT3 activity.  Interestingly, loss-of-
function experiments resulted in the differentiation of similar cell types, suggesting that 
although there is no direct link between these factors, Nanog and STAT3 function in a 
corresponding manner to potentiate ESC’s character (Chambers et al., 2003).    
Indeed, none of these factors can maintain ESC identity alone.  Therefore, Oct-4, 
Nanog and Sox-2 rely upon one another for this intrinsic circuitry to properly function as 
a whole.  At the 4-cell stage of embryonic development, the regulatory circuitry of ESC 
identity is activated by the ubiquitous expression of Oct-4 (Ovitt and Schöler, 1998).  A 
cell-restrictive change in this expression pattern marks the developing embryo’s first cell 
differentiation event, subsequently forming the trophectoderm and the pluripotent ICM.  
Oct-4 maintains the undifferentiated state of the ICM by acting as both a transcriptional 
repressor and activator (Ben-Shushan et al., 1998).  As a member of the POU domain 
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family of octamer-binding proteins, Oct-4 activates or represses its target genes by 
binding to their specific octamer site (Ovitt and Schöler, 1998).  By silencing the 
transcriptional activity of appropriate genes, Oct-4 binding represses the untimely 
expression of two genes, whose expression is later required for embryo implantation 
and pregnancy maintenance.  Alternatively, the binding of Oct-4 to pluripotency-
associated genes, including the Oct-4 gene itself, activates the transcription, and 
subsequent expression, of these developmentally important genes (Ovitt and Schöler, 
1998).   
Oct-4 potentiates its functional activity in ESC through interactions with other 
transcription factors, such as Sox-2 (Loh et al., 2006).   A member of the HMG-domain 
DNA-binding protein family, Sox-2 is absolutely required to maintain ESC identity.  In 
contrast to the regulatory mechanisms utilized by Oct-4 and Nanog, Sox-2 indirectly 
maintains pluripotency by regulating transcriptional activity of Oct-4 (Masui et al., 2007).  
By maintaining the requisite levels of Oct-4 expression, Sox-2 is able to reciprocally 
function with Oct-4 in the direct regulation of ESC pluripotency.  In fact, the 
transcriptional activity of the pluripotency-associated genes, Fgf4, Utf1, and Fbx15 is 
regulated by the collaborative action of Oct-4 and Sox-2 (Yuan et al., 1995; Nishimoto et 
al., 1999; Tokuzawa et al., 2003).  These genes each contain an Oct-4-specific binding 
site and a Sox-2-specific binding site, and, while these two factors bind independently, 
their interaction is essential for proper early embryonic development (Masui et al., 
2007). When this dual binding occurs, Sox-2 forms a ternary complex with Oct-4 protein 
in the enhancer element of the target gene, and, therefore, regulates its expression as a 
binary complex, known as Oct-4/Sox-2 complex (Loh et al., 2006).   In addition to the 
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aforementioned genes, the regulatory region of both Sox-2 and Pou5f1, the gene 
encoding Oct-4, contain binding sites for the Oct-4/Sox-2 complex; therefore, these 
enhancer regions are the direct targets of their own gene products (Chew et al., 2005).   
The Oct-4/Sox-2 complex secured its position at the top of the pluripotent regulatory 
network when researchers found the Nanog proximal promoter also contains an Oct-
Sox element that must be bound by Oct-4 and Sox-2 for Nanog transcription (Kuroda et 
al., 2005; Rodda et al., 2005).   Furthermore, the regulatory elements of each of the 
aforementioned genes contain the Oct-4 site and Sox-2 site within 3-bp of each other, 
which further elucidates a cooperative role in the regulation of pluripotency (Chew et al., 
2005).    
Recently Boyer et al (2005) have shown that Oct-4, Nanog and Sox-2 co-occupy 
regulatory regions of at least 353 genes and two miRNA genes in human ESC.  Indeed, 
prior studies have explored the relationship between these three transcription factors 
which suggested a collaborative effort in the regulation of pluripotency (Kuroda et al., 
2005; Rodda et al., 2005), and yet Boyer et al (2005) were admittedly surprised to 
discover the multitude of genes containing binding sites for Oct-4, Nanog and Sox-2.   In 
addition to their mutual target genes, all three transcription factors contribute to ESC 
pluripotency and self-renewal by also activating their own genes  (Boyer et al., 2005).   
The defining properties of ESC are dependent upon the precise execution of a 
network of activated and repressed genes, regulated in tandem by the transcriptional 
activity of this hierarchical threesome. These transcription factors work synergistically by 
forming a tight and complex intrinsic regulatory circuit that is responsible for maintaining 
the pluripotent state of ESC in vivo.  Within these genes, Oct-4, Nanog and Sox-2 form 
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feedforward loops, which contain two regulators that bind a set of common gene 
targets.  This feature allows for multiple regulatory capabilities that may be responsible 
for ESC’s ability to maintain pluripotency while also upholding the competency to 
properly respond to differentiation signals.  In addition to their shared target genes,   
Oct-4, Nanog and Sox-2 regulate their own gene expression by binding to their own 
promoters, forming an interconnected autoregulatory loop (Boyer et al., 2005).  Due to 
the tight framework of the feedforward and autoregulatory loop formed by Oct-4, Nanog 
and Sox-2, obstruction of the normal relative levels of one of these factors could alter 
the expression of the others, resulting in improper gene expression.  For example, a 
normal ICM and epiblast fail to form in the absence of Oct-4 and Nanog expression.  As 
a result, the cells from which Oct-4 was deleted no longer express Nanog, and the cells 
from which Nanog was deleted no longer express Oct-4 (Chambers et al., 2003).  
Similarly, when Sox-2 is removed from ESC, Oct-4 expression is downregulated (Masui 
et al., 2007) and Nanog transcription is severely compromised (Rodda et al., 2005). 
Nevertheless, the functional reliance upon one another is illustrative of the tight 
regulatory network responsible for the inherent nature of ESC. The expression of Oct-4, 
Nanog and Sox-2 is mandatory for the establishment and maintenance of ESC identity, 
and while their roles in this process are distinct, their functions are cooperative.   
Expression of Oct-4, Nanog, and Sox-2 in Adult Stem Cells 
The expression of Oct-4, Nanog and Sox-2 is invariably responsible for defining 
ESC identity; therefore, they serve as suitable markers for pluripotent cells.   Because it 
is known that the expression of these factors is progressively downregulated with cell 
differentiation, many doubted their presence in ASC.  ASC are generally regarded as 
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being tissue-specific, capable of generating cell lineages specific to their tissue of origin; 
however, recent studies have demonstrated a surprisingly high degree of plasticity 
among ASC.  Within some ASC, researchers have detected the expression Oct-4, 
Nanog, and/or Sox-2, suggesting that these cells may be phenotypically and functionally 
similar to ESC.   
Hematopoietic stem cells derived from porcine umbilical cord blood have been 
shown to express all three central transcription factors characteristic of pluripotent stem 
cells (Carlin et al., 2006).  RT-PCR detected both mRNA and protein level expression of 
Oct-4, Nanog and Sox-2 in these cells. Furthermore, immunocytochemical analysis of 
Oct-4 and Nanog expression indicated that virtually all of the porcine umbilical cord cells 
displayed nuclear immunoreactivity for Oct-4 and Nanog (Carlin et al., 2006).  While 
these findings suggest that these cells are phenotypically similar to pluripotent ESC, 
researchers lacked sufficient evidence to define the potential of these porcine umbilical 
cord cells.  Both  Oct-4 and Sox-2 have been identified in human and non-human MSC 
derived from bone marrow and adipose tissue (Izadpanah et al., 2006).  Early passages 
of these MSC demonstrated that Oct-4 and Sox-2 displayed high levels of co-
localization, which researchers believed may be imperative to MSC’s differentiation 
potentials.  Alternatively, these co-localization levels significantly decreased at higher 
passages, suggesting that gene transcription is somehow inhibited at higher passages 
(Izadpanah et al., 2006). 
  In addition to MSC from bone marrow and adipose tissue, Oct-4 expression has 
also been detected in the cells of the epidermis (Dyce et al., 2004), bronchial 
epithelium, myocardium, pancreas and testes (Ratajczak et al., 2007), disproving the 
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previously-held notion that Oct-4 is expressed only in the germ cells of adult animals 
(Schöler, 1990).  Admittedly, Dyce et al (2004) were surprised by their findings, which 
detected the presence of Oct-4 in porcine skin-oriented sphere (PSOS) cells.  From this 
cell population, individual PSOS cells differentiated into neuron-like, astrocyte-like, and 
adipocyte-like cells, inferring that a population of undifferentiated PSOC stem cells with 
multipotent differentiating capabilities exists within the fetal porcine skin (Dyce et al., 
2004).  Similar results have been reported in a population of fetal somatic stem cells, 
which also expressed Oct-4.  In addition to various mesenchymal organs, these cells 
were shown to give rise to cell types of the mesodermal lineage and migrate into the 
genital ridge, suggesting germ-line transmission might be possible (Kues et al., 2005). 
Undoubtedly, these studies have had a tremendous impact on stem cell biology.  
While these studies present evidence of an accessible, plentiful, and versatile source of 
stem cells for research and cell-based therapy, they contradict the basic principles of 
ASC.  Obviously, this has sparked skepticism and debate among scientist, particularly 
concerning the inherent integrity and capability of ASC. Early reports attributed the 
apparent plasticity of ASC to transdifferentiation (Ferrari et al., 1998; Bjornson et al., 
1999). Transdifferentiation is essentially the total conversion of a cell of one tissue 
lineage into a cell of a completely different lineage, with simultaneous loss of the tissue-
specific markers and function of the original cell type, and attainment of the markers and 
function of the transdifferentiated cell type (Wagers and Weissman, 2004).  This 
process is proposed to occur either directly or through a related process known as 
dedifferentiation.  In this case, differentiated cells are cued to revert back to a less 
mature state (Raff, 2003).    Some scientists question the validity of transdifferention 
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and argue that the stringent criteria for an event to be classified as such have not yet 
been established (Wagers and Weissman, 2004).   Instead, many propose that this 
observed ASC phenomena, mistakenly interpreted as transdifferentiation, is really due 
to spontaneous cell-cell fusion (Ying et al., 2002).  Co-culturing brain cells with ESC 
from the mouse, Ying et al (2002) successfully isolated cells that expressed properties 
similar to ESC.  These cells expressed Oct-4, as well as, ESC markers, alkaline 
phosphatase and stage-specific embryonic antigen.  Furthermore, they exhibited 
dependency on LIF to suppress differentiation, and also demonstrated their ability to 
form embryoid bodies, which were capable of giving rise to neurons.  Unlike ESC, 
however, these selected cells exhibited enlarged nuclei with multiple nucleoli, 
morphological features consistent with hybrid cells.  Chromosome analysis of these 
cells revealed a tetraploid or near tetraploid compliment in these cells, leading Ying et al 
(2002) to conclude that these were, in fact, hybrids generated by spontaneous fusion 
between the mouse ESC and brain cells. Another possible explanation for the apparent 
plasticity of ASC is that multiple adult organs house a small population of pluripotent 
stem cells, which can be stimulated to proliferate and differentiate into lineages other 
than the tissue of origin (Jiang et al., 2002).   Jiang et al (2002) isolated these rare cells 
from bone marrow and demonstrated their ability to differentiate into endothelium, 
ectoderm and endoderm cell lineages in vitro and in vivo.   While the exact mechanism 
responsible for this phenomenon is a source of debate among the scientific community, 





Induced Pluripotent Stem Cells  
 In 1997 Wilmut et al. introduced “Dolly”, a cloned sheep produced from somatic 
cell nuclear transfer (SCNT), demonstrating that somatic cells can be reprogrammed 
when their nuclear components are transferred into oocytes.  In SCNT, the nuclear 
components of a somatic cell are transplanted into an enucleated unfertilized ovum, 
which reprograms the genome of the somatic cell to an embryonic state that is capable 
of generating a cloned animal or producing pluripotent ESC (Wilmut et al., 1997).  While 
much of the ensuing excitement focused on the birth of a cloned animal, many in the 
medical and scientific community were enthused with the prospect of producing patient-
specific ESC for therapeutic use by SCNT.  In recent years, however, the potential 
capabilities of SCNT have been overshadowed by ethical concerns as well as the 
inefficient nature of the procedure, leading researchers to explore alternative 
reprogramming methods for the generation of ESC-like cells.   
 The search for alternatives to SCNT underscores a great deal of the recent 
advancements made in stem cell research.  Indeed, one of the most-publicized topics in 
stem cell research today is induced pluripotent stem cells (iPSC).  iPSC are non-
pluripotent somatic cells engineered to be pluripotent.  Aside from SCNT, there are 
three primary mechanisms of producing iPSC: fusion with ESC, exposure to ESC 
extracts, and by defined factors.   Needless to say, iPSC are believed to be immensely 
beneficial in the study and treatment of disease as the direct reprogramming of somatic 
cells provides an opportunity to generate patient- or disease-specific pluripotent stem 
cells (Nakagawa et al., 2008).   While these three alternative methods of producing 
iPSC are designed to circumvent many of the problems associated with SCNT, they 
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may in fact improve the efficiency of SCNT by providing an optimal source of donor cells 
for reprogramming. The supposed potential of iPSC lies in the fact that these cells are 
morphologically similar to pluripotent ESC and, most importantly, demonstrate key 
characteristics of pluripotent ESC, including expressing stem cell markers, forming 
teratomas containing cells of all three germ layers, and contributing to multiple cell 
lineages (Takahashi and Yamanaka, 2006).    
Wilmut et al. (1997) laid the foundation for a new area of research when they 
demonstrated cell fate can be reversed through SCNT.  Since then, three additional 
methods of reprogramming the nuclei of human somatic cells have been established.  
The first of these reprogramming processes using human cells was introduced in 2005, 
when Cowan et al. revealed that fusion of human ESC with human fibroblasts cells 
results in hybrid cells characteristically similar to ESC.  Interestingly, cell fusion 
experiments using cells of embryonic origin date back to the 1970’s, when Miller and 
Ruddle showed that resulting hybrid cells formed between  murine teratocarcinoma cells 
and thymus cells were phenotypically similar to their pluripotent embryonal carcinoma 
parent (Miller and Ruddle, 1976).   
Over 30 years later, Rathjen et al (2002) produced similar results when they 
fused mouse ESC-derived neuroectoderm with undifferentiated mouse ESC, resulting in 
hybrid cells that expressed pluripotency-associated genes at levels comparable to those 
in ESC.    To test if human ESC were capable of nuclear reprogramming like their 
murine counterpart, Cowan et al (2005) fused human ESC with human fibroblast cells.  
Following fusion, hybrid cells containing both ESC and fibroblast cell chromosomes in a 
single nucleus were formed; however, the hybrid cells exhibited characteristics 
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consistent with the ESC, indicating that the phenotype of human ESC is dominant and 
that they are also capable of  reprogramming human somatic cells (Cowan et al., 2005).  
Unlike the ooplasm of an enucleated oocyte in SCNT, nuclear reprogramming of a 
somatic cell to a less differentiated state through cell fusion is governed by ESC nuclei, 
which reactivates Oct-4 and silences the gene expression of the somatic cell (Do and 
Scholer, 2004; Do and Schöler, 2004; Alberio et al., 2006).  Furthermore, DNA analysis 
showed that the promoter region of Oct-4 in the hybrid cells was demethylated and 
indistinguishable from that found in human ESC, proving that the epigenetic information 
controlling the transcription of pluripotency genes was reprogrammed (Cowan et al., 
2005).  Cell fusion for the production of iPSC is an effective and reliable alternative to 
SCNT; however, because the resulting hybrid cells contain an abnormal ploidy as well 
as nonautologous genes from the pluripotent parent, their therapeutic application is 
significantly hindered (Pralong et al., 2006). 
Although Cowan et al. (2005) believed that their protocol for producing iPSC 
could be beneficial in the study and treatment of human disease, they recognized the 
need to eliminate the ESC chromosomes from the fusion-generated iPSC before they 
could be of therapeutic use.  Indeed, it was experiments such as this that provided the 
inspiration for the development of a cell-free means to reprogramming the nuclei of 
somatic cells to a pluripotent state.  One such way of doing this is through exposure to 
nuclear and cytoplasmic extracts of ESC.  Ha°kelien et al (2002) had previously 
demonstrated the reprogramming abilities of nuclear and cytoplasmic extracts using 
human 293T fibroblast cells and human T cells.  In addition to providing rationale for 
developing cell-extract based systems for reprogramming cell fate, this study developed 
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a highly efficient protocol for reprogramming through cell-derived extracts that has been 
referenced in numerous succeeding studies.  Ha°kelien et al (2002) derived nuclear and 
cytoplasmic extracts from human peripheral blood T cells by lysing the cells from culture 
using a cell lysis buffer.  For the 293T cells to take up the T cell extracts, their cellular 
membrane was permeabilized using Streptolysin O (SLO), which binds to cholesterol in 
the cell membrane and forms holes in the plasma membrane of the cell.  The T cell 
extracts and the permeabilized 293T cells were incubated together for approximately 50 
min and then the plasma membrane was resealed using a CaCl2-containing cocktail 
(Ha°kelien et al., 2002).  Plasma membrane resealing following SLO exposure is 
dependent upon Ca+2, as the  Ca+2 influx triggers a rapid repair process to the 
permeabilized plasma membrane (Walev et al., 2001).   
A more recent study used this same method of extract derivation and membrane 
permeabilization to induce dedifferentiation, associated with genomewide programming 
of gene expression and epigenetic reprogramming of an embryonic gene, in epithelial 
293T cells treated with an extract of undifferentiated human NCCIT carcinoma cells.  As 
a result, the extracts of these ECC were able to induce markers of dedifferenation and 
signs of differentiation plasticity in an otherwise more developmentally restricted cell 
type (Taranger et al., 2005).  In an effort to better understand the molecular processes 
underlying nuclear reprogramming, researchers built upon this study and were able to 
provide evidence of reprogramming of DNA methylation and histone modifications on 
the Nanog promoter and throughout the Oct-4 regulatory region in human epithelial cells 
(Freberg et al., 2007).  In order to identify those cells that had been stably 
reprogrammed to express pluripotency-associated genes, the treated cells in all of the 
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aforementioned studies had to be grown in culture for several weeks, which makes it 
difficult to ascertain reprogramming efficacy as well as complicating further biochemical 
analysis procedures (Bru et al., 2008).  In 2008, however, Bru et al. reported the 
detection of key pluripotency-associated genes in ESC-extract treated cells within a few 
hours of exposure, proving the first stages of reprogramming do not require a long 
incubation period.   Interestingly, the expression of these genes increased in the 48 
hours following exposure to extracts, indicating that long-term reprogramming of gene 
expression had been induced (Bru et al., 2008).  While further studies to validate 
extract-based nuclear reprogramming are needed, it has proven to be an effective 
means to nuclear reprogramming, which may be a more appealing option of generating 
iPSC than by either SCNT or cell fusion.  
 One of the most significant breakthroughs in stem cell research to occur in recent 
years is the production of iPSC by defined factors.  Indeed, it is arguably the most 
celebrated scientific advancement since the birth of “Dolly”.  Like the previously 
mentioned methods of generating iPSC, the ectopic expression of defined transcription 
factors can also generate genetically-tailored stem cells for therapeutic use by 
reprogramming the nucleus of a differentiated cell to function like that of an ESC.  In 
contrast to the production of iPSC by SCNT, fusion with ESC or exposure to ESC 
extracts, the defined factors methodology is far less controversial because it does not 
make use of ESC or oocytes.  Instead, this technique relies upon the actions of four 
transcription factors to elicit pluripotent cells from otherwise developmentally-restricted 
cells.  Considering the transcription factors known to function in the maintenance of 
pluripotency in ESC as well as those specifically expressed in ESC, Takahashi and 
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Yamanaka (2006) selected 24 genes as contenders for factors capable of inducing 
pluripotency in somatic cells.  To determine which genes are critical for reprogramming 
a somatic cell to an ESC-like state, Takahashi and Yamanaka (2006) developed an 
assay system in which a gene’s ability to induce pluripotency was determined by its 
ability to trigger the formation of G418-resistant colonies following its induction to mouse 
embryonic fibroblast cultures by retroviral transduction.   Of these 24 genes, Oct-4, Sox-
2, c-Myc and Klf-4 were identified as the essential factors for generating iPSC directly 
from fibroblast culture (Takahashi and Yamanaka, 2006).  The resultant iPSC exhibited 
morphological features and proliferative properties consistent with ESC, and also 
expressed ESC marker genes.  Furthermore, subcutaneous injection of the iPSC in 
nude mice elicited the formation of teratomas that contained tissues from all three germ 
layers, indicative of the pluripotent state of the iPSC (Takahashi and Yamanaka, 2006).  
The crucial roles Oct-4 and Sox-2 play in maintaining ESC identity are well 
established; therefore, it was not surprising to discover they also serve in the direct 
production iPSC in culture.  However, it was surprising to find that Nanog, whose 
expression is essential to the pluripotent-state of ESC, was dispensable to this process, 
whereas c-Myc and Klf-4 were imperative (Takahashi and Yamanaka, 2006).  c-Myc 
and Klf-4 are proposed to indirectly enhance Oct-4, Sox-2 and Nanog function, 
respectively, in the iPSC.  It is believed that c-Myc may induce global histone 
acetylation in the mammalian genome (Fernandez et al., 2003), which, in turn, 
potentiates Oct-4 and Sox-2 target binding.  Klf-4, on the other hand, may contribute to 
Nanog activation by repressing p53, which is known to suppress Nanog expression in 
ESC during differentiation (Lin et al., 2005).  Indeed, the exact mechanisms these 
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factors employ to induce pluripotency in somatic cells is undetermined, however, their 
ability to do so is universal. Although human ESC differ from murine ESC in many 
aspects, Takahashi et al. (2007) reported the generation of iPSC from adult human 
fibroblast cultures using the same defined factors less than a year after their initial 
study.  The functional uniformity of Oct-4, Sox-2, c-Myc and Klf-4 across species 
suggests that these four factors are fundamentals of a common pluripotency-governing 
system.  Furthermore, the similarities in morphology, proliferation, surface antigens, 
gene expression, epigenetic status of pluripotent cell-specific genes, telomerase 
activity, and pluripotent differentiation ability noted between human iPSC and true 
human ESC (Nakagawa et al., 2008) are similar to those observations between murine 
iPSC and murine ESC (Takahashi and Yamanaka, 2006).   
The ability to produce undifferentiated stem cells without the use of oocytes or 
any form ESC is perhaps the most realistic methodology of generating human ESC for 
government-approved treatment of disease and injury because it sidesteps the ethical 
considerations that have long hindered the therapeutic use of ESC.  Because the 
production of iPSC by defined factors uses an individual’s own cells, possible tissue 
rejection following transplantation is also avoided.  Although the strategy developed by 
Takahashi and Yamanaka for generating iPSC has enormous therapeutic potential, it is 
not an infallible technique.  The greatest problem with these iPSC is the possible 
induction of cancer following transplantation brought about by the use of c-Myc and 
retroviruses for delivering genetic material to the cells to be reprogrammed.  Despite the 
infancy of iPSC research, many notable efforts have been made to reduce the incidence 
of tumorigenicity following iPSC transplantation, including the omission of c-Myc 
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(Nakagawa et al., 2008) and gene delivery without viral integration (Okita et al., 2008; 
Stadtfeld et al., 2008).  Although each of these studies reported the generation of iPSC, 
the number of iPSC yielded in these studies was significantly less compared to the 
number of iPSC produced by the original method proposed by Takahashi and 
Yamanaka (2006).  Nevertheless, the omission of c-Myc from the pool of pluripotency-
inducing transcription factors as well as retroviruses for gene delivery have both proven 
to be effective at reducing the risk of cancerous tumor formation.  
 Although the primary hindrance in this methodology’s application in cell based 
therapy has been tackled with steadfastness, there are still unresolved issues regarding 
the aforementioned techniques of generating iPSC by defined factors. The majority of 
the studies use readily-accessible fibroblast cells as the parental cells to be 
reprogrammed; however, these cells require a minimum of four weeks in order to be 
reprogrammed, resulting in an overall lengthy process. Furthermore, the terminally 
differentiated state of fibroblast cells may account for their relatively low reprogramming 
efficiency.  While cell types such as hepatocytes and neural progenitors are a better fit 
for epigenetic reprogramming, they are impractical for human application as they are 
obtainable only through considerably invasive surgery (Sun et al., 2009). Although iPSC 
research is still in its infancy, the problems regarding the inefficient nature of the 
procedure, culture periods, and establishing an adequate, readily-accessible source of 
cells for reprogramming may already be solved.  Researchers at Stanford University 
School of Medicine have recently reported a 20-fold more efficient production of iPSC 
using ASC derived from lipoaspirates of human adipose tissue at a 2-fold faster 
reprogramming time compared to the original report published by Takahashi and 
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Yamanaka (2006).  Additionally, these iPSC were generated under feeder-free 
conditions using adult human ASC (hASC), which reduces the variability of 
reprogramming commonly associated with mouse feeder cells (Sun et al., 2009).  The 
hASC were isolated from the lipoaspirates of adults between the ages of 40 and 65, and 
then transduced with individual lentiviruses containing human Oct-4, Sox-2, Klf-4 and c-
Myc on two consecutive days.   Comparisons between the adult hASC-derived iPSC 
and true ESC revealed the following similarities: ESC markers, relative levels of 
pluripotency-associated gene expression, morphology, global mRNA patterns, 
hypomethylation patterns within the Oct-4 and Nanog promoter regions and 
differentiation capabilities in vivo and in vitro (Sun et al., 2009).  Previous studies have 
reported many of these same similarities between ESC and iPSC from fibroblast cells, 
and, while there is no marked difference in hASC- and fibroblast cell- derived iPSC 
ability to mimic ESC, only hASC exhibit alkaline phosphatase (AP) activity, a common 
marker of pluripotency in ESC.  Based on this evidence, Sun et al. (2009) speculate that 
the increased efficiency and culture time of the adult hASC-derived iPSC is due to the 
inherently less differentiated state of ASC, which is shown to be more like pluripotent 
cells than terminally differentiated fibroblast cells.   
In addition to their more suitable epigenomic regulatory pattern for 
reprogramming, ASC possess other discernible advantages over other cell types for 
reprogramming. ASC retain a degree of plasticity capable of multiple lineage 
differentiation and are present in many tissues and organs; however, ASC reside as 
very small populations in several of these sources, many of which are obtainable only 
through highly invasive surgeries.   Adipose tissue, on the other hand, represents a 
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readily accessible and plentiful source of ASC in all individuals that is easily isolated 
through a safe and quick lipoaspiration procedure. Furthermore, these cells can be 
isolated the same day as the lipoaspiration procedure and reprogrammed immediately 
following seeding (Sun et al., 2009).  Despite the neoteric state of this study, the feeder-
free extraction of iPSC from adipose-derived adult hASC is immensely promising for the 
future of iPSC in research and therapy.  Indeed, this methodology may prove to be a 
widely accepted means of generating iPSC for clinical application.   
A Look Ahead 
As a frontrunner in both scientific and medical studies for nearly 30 years, 
unwavering interests in stem cells continue to intrigue minds, excite imaginations, and, 
most importantly, fuel research.  Unlike any other known cell type, stem cells, both ESC 
and ASC, can replicate themselves many times over while remaining unspecialized, yet 
they are capable of differentiating into multiple cell lineages.   These characteristics not 
only define the inherent nature of stem cells, but also underline the enormous potentials 
regarding their use in research and medicine. Indeed, it is the supposed ability to cure 
incurable diseases, repair damaged organs and tissues, and heal the lame that has 
consistently fueled efforts in stem cell research.  However, stem cells’ possible 
applications are far-reaching, as their use has been implemented in new drug testing, 
improving biotechnological techniques and enhancing scientists’ understanding of the 
molecular genetic factors responsible for normal and abnormal early embryonic 
development and cell differentiation (Hipp and Atala, 2008).  Before stem cells can be 
consistently and successfully applied in any of these situations, an accessible source of 
competent cells must be established.  The nature of ESC renders them as an ideal 
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source of cells for such applications; however, unresolved technical issues, possible 
immune rejection following treatment, and moral discord impede the current use of 
these cells.  While scientific research may one day correct these existing technical and 
medical impediments, the ethical debate over ESC is not likely to ever be resolved.  
Alternatively, ASC are essentially accessible, safe, and incontrovertible and have been 
established as a viable and successful therapy option for several years.  Although the 
multipotent state of ASC has proven to be sufficient for the treatment of some life-
threatening diseases such as leukemia, it lacks the ability to differentiate into lineages 
outside of its host tissue, therefore, limiting ASC’s therapeutic potential.  Despite these 
limitations, ASC are currently the most practical source of serviceable stem cells. 
The fulfillment of the great promises proposed for stem cells ultimately hinges on 
the sanctioned establishment of an accessible and plentiful source of unspecialized 
cells capable of ubiquitous differentiation and long-term proliferation.  Interestingly, 
recent evidence suggests that such a stem cell population may be engineered to meet 
these requirements.  Reprogramming the genome of ASC to a less mature state is 
currently the most promising and realistic approach towards realizing the therapeutic, 
technological and educational potentials of stem cell application.  The previously-
discussed methods of nuclear reprogramming rely upon a somatic cell’s ability to adopt 
the phenotype of ESC after one of the following procedures: SCNT (Wilmut et al., 
1997), fusion with ESC (Cowan et al., 2005), exposure to ESC extracts (Bru et al., 






EXPRESSION OF PLURIPOTENCY-ASSOCIATED GENES IN BOVINE 
FETAL FIBROBLASTS AND ADIPOSE-DERIVED ADULT STEM CELLS  
Introduction 
The extraordinary nature of ESC lends them the ability to give rise to all the cell 
types of a mammalian organism, an attribute known as pluripotency. The pluripotent 
state of ESC is dependent upon the expression of the genes Oct-4, Nanog and Sox-2, 
which have also been identified as the key transcriptional regulators of pluripotency 
(Boyer et al., 2005; Kuroda et al., 2005; Rodda et al., 2005).  Because differentiation of 
ESC towards cell types of the three germ layers is triggered by the down-regulation of 
Oct-4, Nanog and Sox-2, they have long been considered to be ESC-specific; however, 
recent studies have reported the expression of these genes in some sources of ASC of 
both the mouse and pig (Kues et al., 2005; Carlin et al., 2006).   A variety of somatic cell 
types from several different species, including epidermal cells, bone marrow, adipose 
tissue, bronchial epithelium, myocardium, pancreas, umbilical cord blood and testes, 
have been found to express one or more of these pluripotency-associated genes (Dyce 
et al., 2004; Izadpanah et al., 2006; Ratajczak et al., 2007), suggesting that these 
tissues and organs constitute a population of stem cells that share some phenotypic 
characteristics of ESC.   
The differentiation potential of ASC has been thought to be limited to cell 
lineages present in the organ from which they are derived; however, several studies 
have challenged this notion by demonstrating that some ASC exhibit a remarkably high 
degree of plasticity.  This feature allows ASC to cross lineage barriers and adopt the 
expression profiles and functional phenotypes of cells unique to other tissues (Herzog et 
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al., 2003).  Observations of ASC plasticity have been reported in several different 
somatic cell types, but the majority of these studies have been performed using 
hematopoietic and mesenchymal stem cells derived from bone marrow.  Hematopoietic 
stem cells (HSC) can differentiate into every type of mature blood cell (Wagers and 
Weissman, 2004), whereas mesenchymal stem cells (MSC) are capable of 
differentiating towards the osteogenic, adipogenic, neurogenic, myogenic and 
chondrogenic lineages (Zuk et al., 2001; Mizuno et al., 2002).   The multipotent nature 
of MSC is believed to have several clinical applications for cell therapy and tissue 
engineering, and reports of a broader differentiation repertoire only add to its 
therapeutic potential.  MSC have demonstrated efficacy as therapeutic vectors in animal 
models of lung injury (Ortiz et al., 2003; Ortiz et al., 2007), kidney disease (Kunter et al., 
2006), diabetes (Lee et al., 2006), graft versus host disease (Ringden et al., 2006), 
myocardial infarction (Minguell and Erices, 2006), and various neurological 
disorders(Phinney and Isakova, 2005). 
Although bone marrow-derived MSC have demonstrated immense therapeutic 
potential, their clinical use is hindered by a number of problems.  Access to this cell 
population is obtainable only through a highly invasive and painful procedure, which 
yields very few MSC.  Adipose tissue, on the other hand, represents a readily 
accessible and plentiful source of MSC that can easily be isolated.  Approximately 
400,000 liposuction procedures are performed in the United States annually, yielding 
anywhere from 100 ml to > 3 L of adipose tissue per procedure (Katz et al., 1999).  This 
minimally invasive procedure yields an average of 400,000 cells per mL of lipoaspirate 
tissue in humans (Halvorsen et al., 2001; Zuk et al., 2001; Gimble and Guilak, 2003; 
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Aust et al., 2004).  Alternatively, the volume of human bone marrow taken under local 
anesthesia is typically limited to only 40 ml (Bacigalupo et al., 1992) and contains 
approximately 2.4 x 104 MSC in total (Strem et al., 2005).   
Heightened interest in the potential therapeutic use of ADAS cells has revealed a 
number of similarities between bone marrow-derived MSC and ADAS cells.  Like MSC 
derived from bone marrow, ADAS cells have the potential to differentiate into bone, 
cartilage, tendons, skeletal muscle, and fat when cultivated under lineage-specific 
conditions (Zuk et al., 2001; Wagers and Weissman, 2004; Dicker et al., 2005; Lee et 
al., 2006).  Furthermore, comparative analysis of MSC obtained from bone marrow, 
adipose tissue, and umbilical cord revealed no differences regarding morphology, 
immune phenotype, success rate of isolating MSC, colony frequency, and differentiation 
capabilities (Izadpanah et al., 2006; Kern et al., 2006).  Perhaps the most significant 
similarity between bone marrow-derived MSC and ADAS cells is their ability to suppress 
immunoreactions upon transplantation.  The value of bone marrow-derived MSC in 
allogenic transplantations has been strengthened by reports of their 
immunosuppressive properties that reduce the incidence and severity of graft versus 
host disease, a major complication of allogenic hematopoietic cell transplantations 
(Lazarus et al., 2000; Jorgensen et al., 2003).   Recent studies have found that ADAS 
cells, like MSC derived from bone marrow, suppress immunoreactions (Puissant et al., 
2005a), indicating that ADAS cells may not elicit a cytotoxic T-cell response in vivo 
(Gimble et al., 2007).  While more comprehensive testing is needed, the field of 
regenerative medicine stands to be profoundly impacted if transplanted allogenic ADAS 
cells prove not to evoke an immune response resulting in rejection.   Considering the 
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frequency of liposuction, and the large amount of adipose tissue resulting from each 
procedure, it may be possible to manufacture ADAS cells in large volumes for clinical 
purposes.  Once multiple use product approval takes place and ADAS cells 
manufactured in large volumes, quality assurance and control steps can be streamlined.  
The availability of off-the-shelf allogeneic ADAS cells will reduce the cost of cell-based 
therapies, and allow physicians to use them directly at the point of care rather than 
limiting their use to elective procedures (Gimble et al., 2007).   
Recent studies have reported the presence of Oct-4, Nanog and Sox-2 in 
hematopoietic stem cells derived from porcine umbilical cord blood (Carlin et al., 2006).  
This, along with the expansive repertoire of differentiation potential exhibited by ASC, 
suggests these cells possess characteristics similar to pluripotent cells.  Therefore, ASC 
may be better equipped for complete epigenetic reprogramming than terminally 
differentiated cells.  Considering the abundance and accessibility of adipose tissue, it 
would be advantageous to utilize ADAS cells for nuclear reprogramming.  In the present 
study, we used RT-PCR to analyze bovine adipose-derived adult stem (ADAS) cells and 
fetal fibroblast cells for the presence of the pluripotency-associated genes, Oct-4, 
Nanog and Sox-2.   
Materials and Methods 
Establishment of Primary Cultures 
 Primary cultures of bovine fetal fibroblasts (BFF) were established from two male 
fetuses between 70 and 80 days of age.  A portion of the epidermis was excised from 
the abdominal region of each fetus, finely minced, and washed twice in a solution of 
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Dubelcco’s phosphate buffered saline (DPBS) with Ca+2 and Mg+2, supplemented with 
2% penicillin/streptomycin (P/S) and 2% Fungizone (Gibco, 15290-018).  The tissues 
were placed in 50 ml conical tubes containing a 0.5% collagenase solution (0.5% 
collagenase type I (Gibco, 17100-017) dissolved in Dulbecco’s Modified Eagle Medium 
with high glucose (DMEM) and 1% P/S) and incubated in 5% CO2 at 37˚C for 3 h for 
complete enzymatic dissociation of the tissues.  Following incubation, complete culture 
medium (DMEM with 15% fetal bovine serum (FBS) and 1% P/S) was added to each 
tube to inactivate the enzymatic activity of the collagenase and then centrifuged at 350 x 
g for 5 min.  Cells were resuspended in 5 ml of complete culture medium and cultured in 
75-cm2 flasks under 5% CO2 and 90% humidity at 39˚C.   
 For primary cultures of adipose-derived adult stem cells (ADAS), approximately  
5 g of subcutaneous adipose tissue was collected from the brisket of adult cattle at a 
local abattoir.  The tissues were finely minced, washed in a solution of DPBS with Ca+2 
and Mg+2, 2% P/S and 2% Fungizone twice, and next transferred to sterile Erlenmeyer 
flasks.  For enzymatic digestion, tissues were incubated in a 0.25% collagenase 
solution (DPBS with Ca+2 and Mg+2, 1% Bovine Serum Albumin (BSA), 0.25% 
collagenase type I, 1% P/S, 1% Fungizone) for 3 h in a continuous shaking incubator.  
Afterwards, the samples were transferred to 50 ml conical tubes and centrifuged at   
350 x g for 5 min.  Residual adipose tissue was discarded from the tubes, and the cell 
suspensions were passed through a syringe double filter consisting of 80 µm and      
120 µm nylon filters.  Centrifugation was repeated, followed by a wash in DPBS with 
Ca+2 and Mg+2 supplemented with 1% BSA.  Lastly, cells were resuspended in 1 ml of 
complete culture medium (DMEM, 10% FBS, 1% P/S) and cultured in 12.5-cm2 flasks 
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under 5% CO2 and 90% humidity at 39˚.   After 48 h, the flasks were washed with 2 ml 
of DPBS with Ca+2 and Mg+2, and 2 ml of fresh complete culture media was added 
before being placed back in the incubator.   
Cell Culture Maintenance 
 Two BFF cell lines and three ADAS cell lines were established and maintained in 
culture for the duration of six passages.  Cell cultures were passaged at 90% 
confluence by trypsinization.  Trypsin (0.25% EDTA) was added to confluent cultures to 
disaggregate cells adherent to the flask, which were then counted using a 
hemocytometer.  BFF cells were re-seeded at an initial concentration of 2.1 x 106 cells 
per 75-cm2 flask.  ADAS cells were re-seeded at an initial concentration of 0.7 x 106 per 
25-cm2 flask.   
Cell Cryopreservation  
 At passages two, four and six, cells from all BFF and ADAS cell lines were 
frozen.  Cells that were not re-seeded following trypsinization were resuspended in calf 
serum (CS) supplemented with 10% DMSO (dimethyl sulphoxide) (Sigma, No. D2650) 
and cooled at 1.0˚C/min until reaching -80˚C before storage in liquid nitrogen.  
Approximately 1,000,000 BFF cells and 300,000 ADAS cells were frozen in 1 ml of 
freezing medium per cryovial.   Cells were thawed as needed at room temperature for 





Isolation of Total RNA 
 Total RNA was isolated from ADAS and BFF cell lines at passages two, four and 
six using TRI® Reagent RNA/DNA/Protein Isolation Reagent (Molecular Research 
Center, Inc., Cincinnati, OH).  At 90% confluency, the media was removed and cells 
were lysed directly in the culture flask using 1 ml of TRI® Reagent per 10 cm2.  The 
homogenate was allowed to incubate at room temperature for 5 min and then 
transferred to a 15 ml phase lock gel tube.  For every 1 ml of TRI Reagent used, 0.1 ml 
of BCP reagent (1-bromo-3 chloropropane) (Molecular Research Center, Inc., Cincinnati 
OH)  was added to the tube and allowed to incubate at room temperature for 1 hr.  The 
tube was then centrifuged at 12,000 x g for 15 min at 4˚C to separate the RNA from the 
other cellular components.  After centrifugation, the clear aqueous phase containing the 
RNA was transferred to a 15 ml SuperClear® centrifuge tube (5 PRIME, 2302850), and 
the RNA was precipitated from the aqueous phase using 0.5 ml of isopropanol per 1 ml 
of TRI Reagent used in the initial homogenization.  All samples were stored overnight at 
-20˚C for optimal recovery of RNA.  The following day, the tube was centrifuged at 
12,000 x g for 20 min at 4˚C in Sorvall RC 6 PLUS centrifuge using rotor F13-14x50cy.  
The RNA precipitate forms as a small white pellet on the side and bottom of the tube.  
The supernatant was removed, and the RNA pellet was washed in 2.5 ml of a 75% 
EtOH solution before being centrifuged at 14,000 x g for 10 min at 4˚C.  The RNA pellet 
was then transferred to a 1.5 ml tube containing 1 ml of the 75% EtOH solution and 
centrifuged for a final time at 14,000 x g for 15 min at 4˚C.  Afterwards, the supernatant 
was removed, and the RNA pellet was allowed to air dry.  The RNA pellet was then 
dissolved in 50 µl of water treated with Diethyl pyrocaronate (DEPC)  (Sigma, D5758) 
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and subjected to gel electrophoresis to confirm the presence of RNA before being 
stored at -80˚C. 
Reverse Transcription 
 Total RNA isolated from ADAS and BFF cell lines was reverse transcribed into 
cDNA in a total volume of 20 µl using the iScript cDNA Synthesis Kit (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA).  Each 20 µl iScript RT Reaction mix consisted 
of 15 µl of RNA sample dissolved in DEPC-treated water, 1 µl of reverse transcriptase, 
and 4 µl of iScript reaction mix.  The reaction was conducted at 25˚C for 5 min, 42˚C for 
30 min, a denaturation step of 85˚C for 5 min, and a final holding temperature of 4˚C.   
Reverse Transcription-PCR 
 All ADAS and BFF cell lines were assessed for the presence of Oct-4, Nanog 
and Sox-2 transcripts at passages two, four and six.  Primer sets for Oct-4, Nanog, and 
the reference gene, polyadenylate polymerase (PAP), have previously been verified to 
amplify their respective transcripts in bovine embryos.  All primers were designed from 
bovine gene sequences using the Beacon Designer 4.0 (PREMIER Biosoft 
International) (Table 3.1), and were diluted to 10 mM concentration.  Reactions were 
carried out in a total volume of 25 µl, which consisted of 2.5 µl cDNA, 1 µl of each 
primer (sense and antisense), 12.5 µl of JumpStart™ REDTaq® ReadyMix™ PCR 
Reaction Mix (Sigma, No. P0982), and 8 µl of water.  The program used to amplify all 
genes in each sample involved a denaturating cycle of 1 min at 95˚C; 35 cycles of PCR 
(95˚C for 30 sec, 55˚C for 30 sec, and 72˚C for 30 sec); 4 min at 72˚C; and a final 





























PAP X63436 Sense AAGCAACTCCATCAACTACTG 
Antisense ACGGACTGGTCTTCATAGC 
169 
Table 3.1. Primers used for qRT-PCR analysis 
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gel and sequenced to confirm the correct products were amplified.  To assure that the 
primer sets not amplify genomic DNA, 1 ng of genomic DNA was used as a template for 
the amplification of the target genes.  No amplicons were recovered after RT-PCR of 
genomic DNA (data not shown). 
Validation of Real Time PCR 
 To ensure that the primers for PAP, Oct-4, Nanog and Sox-2 amplified a single 
product in a quantitative manner, amplification efficiency and a correlation coefficient 
from a standard curve was determined for each gene using qRT-PCR (Figure 3.1).    
Purelink™ PCR Purification Kit (Invitrogen, K3100-01) was used to purify PCR products 
in order to individually optimize each transcript in the amplified calibrator cDNA.  A 
standard curve for each gene was generated from the purified PCR product at six 
different 10-fold dilutions. The calibrator cDNA was produced from a mixture of RNA 
from two BFF cell lines at four different passages that was reverse transcribed into 
cDNA using the same method previously described.  All of the target genes had 
acceptable efficiencies (80 to 120%) and correlation coefficients (close to 1.0). 
Quantitative Real Time PCR 
The expression levels of Oct-4, Nanog and Sox-2 in BFF cells treated with ADAS 
cell extracts were quantified using The LightCycler® 480 Real-Time PCR System 
(Roche Applied Science, Indianapolis, IN, USA).  cDNA was amplified using SsoFast™ 
EvaGreen supermix (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The total 20 μl 
real time PCR mix consisted of 2 μl of cDNA, 10 µl of SsoFast™ EvaGreen Supermix,    








Figure 3.1. Melting curves and standard curve obtained using primers 
(sense and antisense) for the amplification of Sox-2.  Six 10-fold 
dilutions of purified PCR product from calibrator cDNA were used to 
generate melting curves (A) and a standard curve (B). 
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each gene.  Within each qRT-PCR plate setup, reactions for the reference gene 
and each gene of interested were performed using the calibrator cDNA, the sample 
cDNA, and a no template negative control.  The PCR program used for the amplification 
of all genes consisted of a denaturing cycle of 30 sec at 95°C; 45 cycles of PCR (95°C 
for 5 sec and 55°C for 20 sec); a melting curve analysis which consisted of 95°C for 5 
sec, 65°C for 1 min, followed by continuous acquisition at 97˚C, with 5 acquisitions per 
˚C; and a final holding temperature of 40°C.  
 Data was quantified using the method for relative quantification in qRT-PCR 
described by Pfaffl (2001).  Values are reported as relative transcription or the n-fold 
difference relative to a calibrator. A mixture of cDNA from BFF cells at multiple 
passages was used as a calibrator for all of the target genes.  PAP was used as the 
internal reference gene. The threshold cycle (Puissant et al.) value of the reference 
gene was used to normalize the target gene signals in each sample. The amount of 
target transcripts relative to the calibrator was calculated using the following equation: 
n-fold difference = Efficiency Target GeneΔCTT/ Efficiency Reference GeneΔCTR, where 
an efficiency of 2 was assumed.  The ΔCTT (for the target gene) value was calculated 
by subtracting the sample CT value of the target gene from the calibrator CT value of the 
target gene. The ΔCTR (for the reference gene) value was calculated by subtracting the 
sample CT value of the reference gene PAP from the calibrator CT value of the 
reference gene. Therefore, all target abundance levels were expressed as n-fold 
differences relative to a calibrator and normalized to the reference gene in order to 





 The presence of Oct-4, Nanog and Sox-2 transcripts in all BFF and ADAS 
samples at passages two, four and six was confirmed by gel electrophoresis following 
RT-PCR (Figure 3.2).  qRT-PCR was subsequently employed in order to quantify Oct-4, 
Nanog and Sox-2 expression levels in these samples.  The relative expression level of 
each gene was determined by calculating the [delta][delta]Ct of each gene relative to the 
calibrator for the given gene and normalized to the reference gene, Poly A Polymerase 
(Tables 3.2 and 3.3). The relative expression levels of Oct-4, Nanog and Sox-2 in BFF 
and ADAS cell samples were generally low, but marked variations in these expression 
levels were observed between cell lines and passage numbers.  Notably, Oct-4, Nanog 
and Sox-2 expression in ADAS#1 at passage two was consistently higher than that of 
the calibrator at passage two; however, gene expression was noticeably reduced in 
passages four and six.  
Discussion 
The differentiation potential of adult stem cells (ASC) has long been thought to 
be limited to cell lineages present in the organ from which they are derived; however, 
several studies have challenged this notion by demonstrating that some ASC exhibit a 
particularly high degree of plasticity.  Unlike terminally differentiated somatic cells, the 
less differentiated state of ASC can assume the functional phenotypes and expression 
profiles of cells unique to other tissues (Herzog et al., 2003). The expansive repertoire 
of differentiation potential exhibited by ASC suggests these cells possess 
characteristics similar to pluripotent cells.  Recent studies reporting the presence of  












Figure 3.2.  Gel Electrophoresis images confirming the presence of 









Sample Oct-4 Nanog Sox-2 
ADAS#1 p2 79.88 138.80 76.58 
ADAS#1 p4 1.28E-4 1.53E-4 1.60E-4 
ADAS#1 p6 2.15E-3 1.36E-3 4.12E-4 
ADAS#2 p2 2.16E-7 14.86 15.36 
ADAS#2 p4 7.57E-3 1.44E-4 3.60E-3 
ADAS#2 p6 3.53E-3 1.47E-3 4.49E-3 
ADAS#3 p2 1.87E-4 9.73E-5 4.30E-6 
ADAS#3 p4 5.41E-4 7.82E-5 8.38E-5 








Table 3.2. Oct-4, Nanog and Sox-2 relative expression levels in ADAS#1, ADAS#2 and 
ADAS#3 at passages two, four and six1  
1The three ADAS cell lines analyzed are designated as ADAS#1, ADAS#2 and 
ADAS#3.  Relative expression of Oct-4, Nanog and Sox-2 was measured in all three of 












Sample Oct-4 Nanog Sox-2 
BFF#1 p2 0.13 2.69E-5 0.08 
BFF#1 p4 0.03 0.19 0.05 
BFF#1 p6 2.12 23.93 2.69E-5 
BFF#2 p2 0.03 0.19 0.06 
BFF#2 p4 3.32E-4 3.88E-4 1.04E-4 








Table 3.3. Oct-4, Nanog and Sox-2 relative expression levels in BFF#1 and BFF#2 at 
passages two, four and six1 
1The two BFF cell lines analyzed are designated as BFF#1 and BFF#2.  Relative 
expression of Oct-4, Nanog and Sox-2 was measured in both of these samples at 
passages two, four and six, denoted as p2, p4 and p6, respectively 
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 (Kues et al., 2005; Carlin et al., 2006) provide further evidence in support of phenotypic 
and functional similarities between ASC and ESC.  It should be noted that, although 
numerous studies have reported the expression of one or more pluripotency-associated 
genes in several sources of ASC, the biological and functional significance of their 
expression in these cells remains largely unknown.  In the present study, we analyzed 
bovine ADAS cell and BFF cells for the presence of the pluripotency-associated genes, 
Oct-4, Nanog and Sox-2.   
Like other studies that have analyzed sources of ASC for Oct-4, Nanog and   
Sox-2 expression, we report the presence of Oct-4, Nanog and Sox-2 transcripts in 
bovine ADAS cells and BFF cells (Dyce et al., 2004; Kues et al., 2005; Carlin et al., 
2006; Izadpanah et al., 2006; Ratajczak et al., 2007).  While transcripts for all three 
pluripotency-associated genes were detected in all samples, we found their expression 
to be highly variable between cell lines and passage numbers.   It should be noted that 
among these studies, only the study by Carlin et al. (2006) reported the presence of all 
three genes.  The other studies only reported detecting one or two of these genes; 
however, not all these studies analyzed cells for Oct-4, Nanog and Sox-2 expression.  
In these studies, ASC were evaluated and found positive for the expression of other 
pluripotency-associated genes, such as Stat3 (Dyce et al., 2004; Kues et al., 2005), 
Rex-1 (Izadpanah et al., 2006), and Akp2 (Kues et al., 2005).  In addition, many of 
these studies extended their analysis of ASC beyond gene expression and presented 
evidence of multilineage differentiation (Dyce et al., 2004; Kues et al., 2005; Izadpanah 
et al., 2006), extended self-renewal capabilities (Dyce et al., 2004; Kues et al., 2005), 
alkaline phosphatase activity (Carlin et al., 2006), clonal-generating capacity (Dyce et 
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al., 2004), and telomerase activity (Izadpanah et al., 2006).  While these types of tests 
are beyond the scope of our study, it is plausible to speculate that bovine ADAS cells 
BFF cells also demonstrate these characteristics.    
The presence of Oct-4, Nanog and Sox-2 transcripts in cells which are not 
inherently pluripotent leads us to believe that there may be another level of regulation at 
the translational level for these genes.  Although our study did not examine BFF cells 
and ADAS cells for the expression of these proteins, a study by Page et al. (2009) 
provides evidence in support of our belief.  Page et al. (2009) reported basal expression 
of mRNA for Oct-4, Nanog and Sox-2 in primary adult human fibroblasts; however, 
neither Western blot analysis nor Immunocytochemistry detected the presence of these 
proteins.  Interestingly, Oct-4, Nanog and Sox-2 proteins were detected in adult human 
fibroblasts cultured in a reduced oxygen atmosphere and in the presence of FGF2.  
FGF2 has been found to be essential in the maintenance of Oct-4, Nanog and Sox-2 
expression and pluripotency (Levenstein et al., 2006).  While Page et al. (2009) had not 
yet determined the functional relationship between FGF2 and stem cell expression in 
dermal fibroblasts, they did demonstrate that modifications to the in vitro culture 
environment triggered translation of Oct-4, Nanog and Sox-2 and their appropriate 
translocation to the cells’ nuclei.  Importantly, their results suggest that alteration of cell 
fate may depend not only on the induction of new transcription, but also on the 
mechanisms regulating posttranscriptional modifications and translation (Page et al., 
2009). 
The results of the present study support the notion that BFF cells and ADAS cells 
are less differentiated than other somatic cells. It has been suggested that the genome 
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of less differentiated cells may be more amenable to reprogramming or require less 
reprogramming following the induction of pluripotency either by SCNT or another 
experimental strategy (Rideout et al., 2001). Currently, the overall efficiency of SCNT is 
between 0-3% (number of live offspring as a percentage of the number of nuclear 
transfer embryos) (Paterson et al., 2003).  While several factors have been identified as 
contributors to the inefficiency of the procedure, incomplete epigenetic reprogramming 
is considered the primary reason for developmental failure of SCNT embryos (Li et al., 
2003).  Because of the high degree of plasticity demonstrated by ADAS cells, it is likely 
that these cells have an epigenomic regulatory pattern that is closer to pluripotent ESC 
than terminally differentiated somatic cells (Sun et al., 2009).  Therefore, the unique 
epigenetic landscape of ADAS cells may present fewer barriers for reprogramming, 













CELL EXTRACT-BASED NUCLEAR REPROGRAMMING OF SOMATIC 
CELLS  
Introduction 
In its’ simplest form, the term nuclear reprogramming has been defined as the 
molecular dominance of one distinct cell type over another (Western and Surani, 2002). 
Because the goal of most reprogramming studies is to reinstate developmental 
pluripotency in differentiated somatic cells, the term has come to specifically describe 
the reversal of the differentiated state of a mature cell to one that is characteristic of the 
undifferentiated embryonic state (Hochedlinger and Jaenisch, 2006).  To date, the 
majority of reprogramming studies employ the use of SCNT; however, the relatively 
inefficient nature of SCNT has overshadowed its benefits and limited its application.  
While several factors have been identified as contributors to the inefficiency of the 
procedure, incomplete epigenetic reprogramming is considered the primary reason for 
developmental failure of SCNT embryos. The need for a more amendable and efficient 
means of reprogramming resulted in the development of three additional experimental 
approaches.   Aside from SCNT, there are three experimental strategies used to induce 
pluripotency in differentiated somatic cells: fusion with ESC (Cowan et al., 2005), 
exposure to ESC extracts (Bru et al., 2008), and by defined factors (Takahashi and 
Yamanaka, 2006).  Takahashi and Yamanaka (2006) not only provided a fourth 
approach to successful nuclear reprogramming, they also coined the term “induced 
pluripotency stem cell” (iPSC).  iPSC specifically refers to the generation of pluripotent 
stem cells from non-pluripotent cells by induced gene expression; however, the term is 
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now commonly used to refer to all non-pluripotent cells that have been engineered to 
become pluripotent, regardless of which reprogramming method is employed.  
In all of the aforementioned reprogramming strategies, differentiated somatic 
cells are reverted to an ESC-like state as a result of changes in the epigenome.  
Epigenetic changes are heritable modifications to DNA or chromatin that allow 
differentiated cells to perpetuate the molecular memory needed to retain their identity 
(Tada et al., 1997; Jones and Takai, 2001).  Although epigenetic modifications are 
heritable, all four reprogramming methodologies have demonstrated that these 
modifications can be experimentally reversed.  Histone modifications and DNA 
methylation are two of the major epigenetic modifications that play a significant role in 
regulating gene expression. The principle function of epigenetic modifications is the 
regulation of repressed genes not required in specific cell types at specific stages in 
development (Wolffe and Matzke, 1999).  For example, when the cells of the ICM 
differentiate towards their specific lineages, the promoter regions of the transcription 
factors Oct-4, Nanog and Sox-2 are methylated, rendering them transcriptionally 
inactive (Nichols et al., 1998; Chambers et al., 2003; Okumura-Nakanishi et al., 2005; 
Yeo et al., 2007).  In order to reinstate Oct-4, Nanog and Sox-2 expression, the 
opposite epigenetic modification, demethylation, must occur.  Studies have shown 
partial DNA demethylation in restricted areas of the Oct-4 regulatory region as well as 
demethylation of the Nanog promoter in iPSC produced by SCNT, fusion with ESC, and 
by defined factors (Tada et al., 1997; Cowan et al., 2005; Takahashi and Yamanaka, 
2006; Blelloch et al., 2007).   Similarly, Freberg et al., (2007) reported demethylation 
throughout the Oct-4 regulatory region and the Nanog promoter in 293T cells treated 
55 
 
with ESC extracts, which, along with histone modifications, resulted in the up-regulation 
of Oct-4 and Nanog.  Although functional reprogramming of somatic cell nuclei towards 
pluripotency involves several complex molecular events and epigenetic changes, it is 
evident that demethylation is a primary epigenetic determinant in nuclear 
reprogramming, irrespective of the approach.  Therefore, each reprogramming strategy 
must possess the necessary regulatory components required to elicit demethylation as 
well as the other appropriate epigenetic changes responsible for reinstating pluripotency 
in differentiated somatic cells. 
Nuclear reprogramming techniques are believed to be immensely beneficial in 
the study and treatment of disease as the direct reprogramming of somatic cells 
provides an opportunity to generate patient- or disease-specific pluripotent stem cells 
(Nakagawa et al., 2008). While all four experimental techniques have demonstrated the 
ability to successfully reprogram gene expression and promote pluripotency in 
terminally differentiated cells (Thomson et al., 1998; Cowan et al., 2005; Takahashi and 
Yamanaka, 2006; Bru et al., 2008), not all of the methods are suitable for generating 
iPSC for clinical use.  Aside from the obvious ethical issues regarding nuclear 
reprogramming by SCNT and fusion with ESC, major technical obstacles impede their 
clinical applications.  The inefficient nature of SCNT, coupled with the fact that it is a 
technically challenging procedure, make it unlikely that SCNT could be performed on a 
large scale to derive pluripotent cell lines routinely for every patient (Amabile and 
Meissner, 2009).  Although nuclear reprogramming by fusion with ESC circumvents 
these hindrances, abnormal ploidy and the presence of nonautologous genes from the 
pluripotent parent cells prevent the therapeutic use of pluripotent hybrid cells (Pralong et 
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al., 2006). For this approach to be viable, a practical means of removing the nucleus of 
the ESC from the hybrid cell must be developed in order to generate diploid customized 
cells for transplantation therapy.  It will be difficult, if not impossible, to selectively 
eliminate the entire set of ESC chromosomes from the hybrid cells if future research 
determines DNA replication is required for reprogramming (Hochedlinger and Jaenisch, 
2006).   
Progress in the science of SCNT and ESC cell fusion-based reprogramming may 
make it possible to overcome these technical obstacles; however, the therapeutic 
potential of these reprogramming techniques will most likely continue to be hindered by 
controversy.  Nonetheless, the value of these techniques should not be overlooked.  
Indeed, it is years of SCNT experiments that have proven the nucleus of most, if not all, 
adult cells retains nuclear plasticity and can be reset to an embryonic state (Amabile 
and Meissner, 2009).  This, along with logistical and legislative limitations, fueled the 
development of alternative reprogramming mechanisms.  While these techniques were 
originally designed to circumvent the problems associated with SCNT, they may in fact 
improve the efficiency of SCNT by providing an optimal source of donor cells for 
reprogramming. Currently, the overall efficiency of SCNT is between 0-3% (number of 
live offspring as a percentage of the number of nuclear transfer embryos) (Paterson et 
al., 2003).  However, blastocyst rates and the number of live births have been shown to 
dramatically increase when ESC are used as donor cells (Rideout et al., 2001), 
suggesting that the genome of less differentiated cells is better equipped for complete 
epigenetic reprogramming than that of a differentiated somatic cell.  Although SCNT is 
not suitable for generating therapeutic cells, the ability to produce genetically superior 
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livestock has established SCNT as an invaluable tool in commercial livestock 
production.  If cell extracts or defined transcription factors are used to reprogram the 
somatic cells to be used as donor cells to a less differentiated state, the efficiency of 
cellular reprogramming during SCNT may be enhanced.   
Extract-based nuclear reprogramming of differentiated somatic cells is an 
attractive approach towards the production of iPSC for several reasons.  Aside from 
providing optimal donor cells for SCNT, in vitro reprogramming using cell extracts 
presents innovative technological and commercial benefits.  Two advantages of extract-
mediated nuclear reprogramming are the absence of introduction of ESC chromosomes 
into the cell to be reprogrammed, and the possibility of identifying reprogramming 
factors and mechanisms of reprogramming (Collas, 2007).  Extract-derived factors are 
presumably not permanently active in target cells but turn over at kinetics corresponding 
to their half-lives.  By circumventing the use of whole cells, the difficulties associated 
with removal of extra chromosomes are eliminated (Dittmar et al., 2009).  Furthermore, 
the use of permeabilized cells allows the reprogramming factors to access the interior 
directly, which may not only be more effective but has the advantage of being useful 
without having a great deal of prior knowledge of regulatory mechanisms controlling cell 
function.  From a commercial standpoint, extract-based reprogramming is far more 
practical than SCNT.  Cells are the source of reprogramming material, which, unlike 
oocytes, can be grown in large numbers, and, if necessary, can be transformed to 
produce a consistent supply of reprogramming material.  Importantly, in vitro 
reprogramming may be applied to many cell types and thus has potential to treat many 
diseases (Collas, 2007).    
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The hunt for a pluripotent stem cell suitable for therapeutic applications 
underscores the bulk of nuclear reprogramming studies.  Reprogramming somatic cells 
towards pluripotency by exposure to ESC extracts avoids ethical and legal issues 
regarding human cloning and the production of ESC from human embryos because it 
does not use oocytes or intact ESC (Collas, 2007); however, the use of extracts from 
ESC is still somewhat controversial.  Nevertheless, it may still be possible to produce 
replacement cells suitable for therapeutic applications by extract-based reprogramming.  
Because the genome of ASC is inherently less differentiated than other somatic cells, 
exposing them to extracts of other ASC may drive them further towards an 
undifferentiated state.  Although this treatment will not produce cells that mimic true 
ESC, it has been suggested that it may not be necessary to produce a fully 
reprogrammed cell for cell replacement therapeutic applications (Collas, 2007).  
Extensive studies are required to validate this hypothesis, and a great deal more work is 
needed before this or any reprogramming technique is systematically employed to 
produce cells for therapeutic applications.   
Extract-based reprogramming using ASC is a promising and plausible approach 
towards the production of replacement cells for therapeutic purposes; however, it may 
be several years before this reprogramming technology is applied in a clinical setting.  
The field of animal agriculture, on the other hand, may be able to reap the rewards of 
this reprogramming technique soon.  In addition to enhancing commercial livestock 
production, SCNT is an ideal procedure for introducing specific genetic modifications in 
farm animals.  The production of transgenic animals not only provides a means of 
studying genes involved in a variety of biological systems and disease processes, but 
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transgenic animals may also be used as bioreactors for the production of 
pharmaceuticals and perhaps even serve as organ donors for the human population 
(Edwards et al., 2003).  Moreover, SCNT has been used to successfully generate 
histocompatible tissues, addressing one of the major challenges in transplantation 
medicine (Lanza et al., 2002).  The benefits of SCNT, however, are often overshadowed 
by the relatively inefficient nature of the procedure.  Incomplete epigenetic 
reprogramming is considered the major cause of the developmental failure of cloned 
embryos (Li et al., 2003).  This is likely due to the extensive chromatin modifications 
characteristic of terminally differentiated somatic cells.  It has been suggested that the 
nucleus of a less differentiated cell may be more amenable to or require less 
reprogramming than the nucleus of a fully differentiated somatic cell (Rideout et al., 
2001).  Because ASC are inherently less differentiated than other somatic cells, readily 
reverting their genome to an even less differentiated state may be possible through 
extract exposure. 
Considering the abundance, accessibility, and differentiation capabilities 
demonstrated by cells isolated from adipose tissue, we believe adipose-derived adult 
stem (ADAS) cells are an ideal candidate for extract-based reprogramming.  This belief 
is further supported by our findings which confirm the presence of Oct-4, Nanog, and 
Sox-2 in bovine ADAS cells.  Currently, the vectors available for these transcription 
factors are either mouse or human, and the response between species is not known.    
Based on this, we hypothesize that nuclear and cytoplasmic extracts derived from 
ADAS cells possess the ability to increase Oct-4, Nanog and Sox-2 expression levels in 
other ASC.   
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Materials and Methods 
Experiment 1 Experimental Design 
 Nuclear and cytoplasmic extracts were derived from four different ADAS cell lines 
at passage two.  These ADAS cell extracts, which served as the reprogramming 
material in our extract-based reprogramming system, were incubated with reversibly-
permeabilzed cells of two different BFF cell lines at various passages.  Following 
incubation, the membranes of the permeabilized BFF cells were resealed, and the cells 
were allowed to culture for 4-5 days in complete culture medium.  Oct-4, Nanog and 
Sox-2 expression in these cells was determined using qRT-PCR. 
Experiment 2 Experimental Design 
 To further investigate the extract-based reprogramming system, BFF cells were 
also exposed to nuclear and cytoplasmic extracts derived from hESC.  Extracts were 
derived from a single hESC line, which had been expanded and cultured under 
standard ESC culture guidelines.  Cells from the same BFF cell lines were reversibly 
permeabilized before incubating in hESC extracts.  After resealing the plasma 
membrane of the BFF cells, the cells were plated and allowed to culture for 
approximately 5 days.  Oct-4, Nanog and Sox-2 expression levels in these cells were 
determined using qRT-PCR.   
Establishment of Primary Cultures 
 Primary cultures of bovine fetal fibroblasts (BFF) were established from two male 
fetuses between 70 and 80 days of age.  A portion of the epidermis was excised from 
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the abdominal region of each fetus, finely minced, and washed twice in a solution of 
Dulbecco’s phosphate-buffered saline (DPBS) with Ca+2 and Mg+2, supplemented with 
2% penicillin/streptomycin (P/S) and 2% Fungizone (Gibco, 15290-018).  The tissues 
were placed in 50 ml conical tubes containing a 0.5% collagenase solution (0.5% 
collagenase type I (Gibco, 17100-017) dissolved in Dulbecco’s Modified Eagle Medium 
with high glucose (DMEM) and 1% P/S) and incubated in 5% CO2 at 37˚C for 3 h for 
complete enzymatic dissociation of the tissues.  Following incubation, complete culture 
medium (DMEM with 15% fetal bovine serum (FBS) and 1% P/S) was added to each 
tube to inactivate the enzymatic activity of the collagenase and then centrifuged at 350 x 
g for 5 min.  Cells were resuspended in 5 ml of complete culture medium and cultured in 
75-cm2 flasks under 5% CO2 and 90% humidity at 39˚C.   
 For primary cultures of adipose-derived adult stem cells (ADAS), approximately  
5 g of subcutaneous adipose tissue was collected from the brisket of adult cattle at a 
local abattoir.  The tissues were finely minced, washed in a solution of DPBS with Ca+2 
and Mg+2, 2% P/S and 2% Fungizone twice, and transferred to sterile Erlenmeyer 
flasks.  For enzymatic digestion, tissues were incubated in a 0.25% collagenase 
solution (DPBS with Ca+2 and Mg+2, 1% bovine serum albumin (BSA), 0.25% 
collagenase Type I, 1% P/S, 1% Fungizone) for 3 h in a continuous shake incubator.  
Afterwards, the samples were transferred to 50 ml conical tubes and centrifuged at   
350 x g for 5 min.  Residual adipose tissue was discarded from the tubes, and the cell 
suspensions were passed through a Millipore double filter consisting of 80 µm and 120 
µm nylon filters.  Centrifugation was repeated, followed by a wash in DPBS with Ca+2 
and Mg+2 supplemented with 1% BSA.  Lastly, cells were resuspended in 1 ml of 
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complete culture medium (DMEM, 10% FBS, 1% P/S) and cultured in 12.5-cm2 flasks 
under 5% CO2 and 90% humidity at 39˚ C.   After 48 h, the flasks were washed with 2 
ml of DPBS with Ca+2 and Mg+2, and 2 ml of fresh complete culture media was added 
before being placed back in the incubator.   
Cell Culture Maintenance 
 BFF and ADAS cell cultures were passaged at 90% confluence and maintained 
for the duration of six passages.  Trypsin (0.25% EDTA) was added to confluent 
cultures to disaggregate cells adherent to the flask, which were then counted using a 
hemocytometer.  BFF cells were re-seeded at an initial concentration of 2.1 x 106 cells 
per 75-cm2 flask.  ADAS cells were re-seeded at an initial concentration of 0.7 x 106 per 
25-cm2 flask.   
 hESC were provided by Dr. Kenneth Eilertsen’s laboratory at Pennington 
Biomedical Research Center.  Frozen hESC were quickly thawed in a 37˚C water bath, 
and immediately transferred to a sterile 50 ml tube.  A total volume of 10 ml of 
mTeSR®1 (STEMCELL Technologies Inc., Vancouver, BC, Canada) complete culture 
medium was added drop wise to the tube, and then centrifuged at 200 x g for 4 min.  
The supernatant was discarded, and the cell pellet was resuspended in 2 ml of 
mTeSR®1.  The cell suspension was transferred to 1 well of a 6-well plate that 
contained prepared mouse embryonic fibroblast (MEF) feeder layer cells and placed in 
a 37˚C incubator.  The media was replaced with fresh mTeSR®1 media daily.    
 hESC colony growth was monitored daily to ensure the cells remained 
undifferentiated.  Before the colonies contacted each other, they were passaged using 
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dispase (1 mg/ml).  Approximately 1ml of dispase was added to each well of a 6-well 
plate, and then placed in a 37˚C incubator for 7 min.  Afterwards, the dispase solution 
was aspirated, and the wells were washed twice in 2 ml of DMEM/F12.  A volume of 2 
ml of mTeSR was added to each well, and the hESC colonies were scrapped from the 
plate using a cell scrapper.  The detached cell aggregates were transferred to a sterile 
15 ml tube.  Each well was rinsed with an additional 2 ml of mTeSR and added to the 15 
ml tube.  The hESC were evenly split into each well of a 6-well plate coated with 
Matrigel and placed back in the incubator.  Because residual MEF cells were likely 
present in this initial hESC population, the cells were passaged twice before extracts 
were derived.   
 Matrigel-coated plates were prepared by mixing thawed BD Matrigel™ Basement 
Membrane Matrix (BD Biosciences, Franklin, NJ, USA) with approximately 25 ml of 
DMEM/F12.  A total volume of 1 ml of the diluted Matrigel solution was added to each 
well of a 6-well plate and allowed to incubate at RT for at least 1 hr before plating hESC.   
Derivation of Cell Extracts 
 Nuclear and cytoplasmic extracts were derived from ADAS cell lines at passage 
two.  At 90% confluency, cells were trypsinized and centrifuged at 300 x g for 10 min at 
4˚C.  Alternatively, hESC were harvested using dispase (1 mg/ml) and centrifuged at 
300 x g for 5 min at RT.  All cells were washed twice in ice-cold DPBS with Ca+2 and 
Mg+2, and then resuspended in approximately 9.5 ml of ice-cold Cell Lysis Buffer 
without Halt™ Protease Inhibitor Cocktail (100 mM HEPES, pH 8.2, 50 mM NaCl, 1 mM 
dithioreitol (DTT), 0.1 phenylmethylsulfonyl fluoride (PMSF), 5 mM MgCl2, Milli-Q H20).  
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The cell suspension was centrifuged at 300 x g for 10 min at 4˚C, and the resulting 
supernatant was discarded.  To initiate cell lysis, cells were resuspended in 250 µl of 
cell lysis buffer containing 10 µl of Halt™ Protease Inhibitor Cocktail (100 X) (Thermo 
Scientific, 1860932) and 5 µl of 0.5 M EDTA and held on ice for approximately 45 min.  
The cell suspension was then transferred to a glass pestle on ice for Dounce 
Homogenization.  When at least 90% of the cells were lysed, the cell lysate was 
transferred to pre-chilled 1.5 ml tubes and centrifuged at 15,000 x g for 15 min at 4˚C.  
The supernatant (extract) was collected, and 100µl aliquots were prepared and held on 
ice. 
 Extract Toxicity Assessment 
 A cell toxicity test was performed for each extract preparation.  To test the 
extracts, approximately 50,000 adult bovine fibroblast cells were placed in a 1.5 ml tube 
with     30 µl of extract and incubated for 1 h in a 37˚C water bath.  A 3 µl sample was 
then placed on a microscope slide and cell morphology was assessed (Figure 4.1).  
Cell Permeabilization Assay 
 Because successful reversible permeabilization of cells with Streptolysin O (SLO) 
requires selection of the correct toxin, we first sought to identify the SLO concentration 
that results in permeabilization of 60 to 80% of the total cell population within 10-15 min 
(Walev et al., 2001).  A 10 µg/ml stock solution of SLO was prepared by dissolving the 
SLO in 10 mM of DTT, and 10 µL aliquots were prepared.  The SLO stock solution was 









  Figure 4.1. Intact fibroblast cells were placed in a 1.5 ml tube with 30 µl of extract 
and incubated for 1 hr in a 37˚C water bath.  A 3 µl sample was then placed on a 
microscope slide and cell morphology was assessed.  Cells shown in  (A) 
survived exposure to the extract whereas cells in (B) did not survive extract 
exposure and will die in subsequent culture.  Batches of extract giving rise to 
such cells should be discarded. Cells shown in (C) were exposed to cell lysis 
buffer alone.  
                                                                                            (www.collaslab.com) 
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remaining SLO stock solution aliquots were stored at -20˚C.  Adult bovine fibroblast 
cells were harvested as per standard procedure, and aliquots of approximately 170,000 
adult bovine fibroblast cells were resuspended in 488 µl of ice-cold DPBS without Ca+2 
and Mg+2 containing 50 µg/ml of propidium iodide.  The cell suspensions were placed in 
a 37˚C water bath for 2 min, and then individually treated with 12 µl of either the 1:5, 
1:10, 1:20, or 1:30 SLO dilutions.   A fifth aliquot of 170,000 adult bovine fibroblast cells 
served as a control, and, therefore, did not receive either SLO or DPBS without Ca+2 
and Mg+2.  After incubating for 50 min in a 37˚C water bath, the cells were centrifuged at 
300 x g for 5 min at 4˚C, and the supernatant was discarded.  To initiate resealing of the 
plasma membrane, the cells were resuspended in 1.5 ml of complete culture medium 
containing 2 mM CaCl2 (DMEM with 10% FBS and 1% P/S).  Each 1.5 ml cell 
suspension was evenly distributed between 3 wells of a 24-well plate and allowed to 
culture for 1 h in a 5% CO2 incubator.  Cells were observed by epifluorescence 
microscopy for the uptake of propidium iodide, which is indicative of successful 
permeabilization, resealing, and reseeding.  SLO concentrations that resulted in the 
positive staining of 60 to 80% of the cells were selected.  Based on the results of the 
assay, we concluded that SLO stock diluted 1:20 in DPBS without Ca+2 and Mg+2 was 
sufficient for our experimentations.   
Reversible Permeabilization of Donor Cells 
Prior to harvesting BFF cells for reversible permeabilization, a 10 µl aliquot of the 
SLO stock was removed from the -20˚C freezer and allowed to thaw at room 
temperature.  The SLO working solution used for cell membrane permeabilization was 
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prepared by diluting the SLO stock 1:20 in ice-cold DPBS without Ca+2 and Mg+2 and 
held on ice until use.   
BFF cells used as donor cells were harvested by the same methods previously 
described.  The cells were washed in 10 ml of ice-cold DPBS without Ca+2 and Mg+2 and 
centrifuged at 300 x g for 10 min at 4˚C.  Because Ca+2 inhibits SLO activity, the cells 
were washed two additional times in order to ensure complete removal of Ca+2.  After 
the final wash, the cell pellet was resuspended in 1 ml of DPBS without Ca+2 and Mg+2. 
Aliquots of approximately 100,000 cells were transferred to pre-chilled 1.5 ml tubes and 
centrifuged at 300 x g for 5 min at 4˚C.  The supernatant was removed, and the cell 
pellets were carefully resuspended in 488 µl of ice-cold DPBS without Ca+2 and Mg+2.  
The tubes were placed in a 37˚C water bath for 2 min before 12 µl of the SLO working 
solution was added to each tube.  The tubes were then incubated horizontally in a 37˚C 
water bath for 50 min.  At the end of the incubation period, the tubes were placed on ice 
and 500 µl of ice-cold DPBS without Ca+2 and Mg+2 was added to each tube.  Prior to 
extract exposure, the permeabilized BFF cells were centrifuged at 300 x g for 5 min at 
4˚C, and the supernatant removed. 
In Vitro Reprogramming  
An ATP-Regenerating System was prepared by mixing ATP (100 mM), 
phosphocreatine (1 M), creatine kinase (2.5 mg/ml), and GTP (10 mM) in a 1:1:1:1 ratio.      
A volume of 5 µl of the ATP-Regenerating System mix was added to each 100 µl aliquot 
of ADAS cell extracts and then transferred to the 1.5 ml tubes containing 100,000 
permeabilized BFF cells.  Controls for each BFF cell line were prepared by adding equal 
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volume of DPBS with Ca+2 and Mg+2 to 100,000 permeabilized cells.  The cells were 
incubated horizontally in a 37˚C water bath for 1 h.  At the end of incubation, 500 µl of 
complete culture medium containing 2 mM CaCl2 (added from a 1 M CaCl2 stock 
solution) was added to each 1.5 ml tube to reseal the plasma membrane of the BFF 
cells.  The contents of each tube were then transferred to one Matrigel-coated well of a 
24-well plate and cultured for approximately 4 h in a 5% CO2 incubator at 37˚C before 
the replacing the 2 mM CaCl2-containing culture media with fresh complete culture 
medium (without added CaCl2).  The cells were cultured in a 5% CO2 incubator at 37˚C 
until assessment of reprogramming efficiency.   
Isolation of mRNA 
 Approximately 72 h after extract exposure, mRNA was isolated from both 
treatment and control cells using Dynabeads® mRNA Direct™ Micro Kit (Dynal Biotech, 
Inc., Lake Success, NY, USA) as described previously by Wrenzycli et al (2001).  After 
cells were harvested by trypsinization, they were washed in 1 ml of DPBS with Ca+2 and 
Mg+2 and 300 µl of lysis/binding buffer (100 mM Tris HCl (pH 8.0), 500 mM LiCl, 10 mM 
EDTA, 1% lithium dodecylsulfate, and 5 mM dithiothreitol).  DNA was sheared from the 
cells using a 1 ml syringe and a 21 gauge needle before being centrifuged at 12,000 x g 
for 15 sec.  Following a 10 min incubation, pre-washed Dynabeads® (50 µl) were added 
to the sample solute, and the sample poly(A)+ RNAs were allowed to anneal to the 
beads while rotating on a hybridization mixer for 10 min. The beads were separated 
from the mix using a Dynal MPC-E-1 magnetic separator. The samples were washed 
twice in 50 μl of wash buffer A (10 mM Tris HCl (pH 8.0), 150 mM LiCl, 1 mM EDTA, 
and 0.1% lithium dodecylsulfate) and twice in 50 μl wash buffer B (10 mM Tris HCl (pH 
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8.0), 150 mM LiCl, and 1 mM EDTA). The mRNA was eluted from the beads by adding 
15 μl of nuclease-free water and incubating for 2 min in a 70˚C water bath.  The mRNA 
was separated from the beads using the Dynal MPC-E-1 magnetic separator and 
immediately used for reverse transcription. 
Reverse Transcription 
 The freshly-isolated mRNA was reverse transcribed into cDNA in a total volume 
of 20 µl using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA, 
USA).  Each 20 µl iScript RT Reaction mix consisted of 15 µl of sample mRNA, 1 µl of 
reverse transcriptase, and 4 µl of iScript reaction mix.  The reaction was conducted at 
25˚C for 5 min, 42˚C for 30 min, a denaturation step of 85˚C for 5 min, and a final 
holding temperature of 4˚C.   
Validation of Real Time PCR 
 To ensure that the primers for PAP, Oct-4, Nanog, and Sox-2 amplified a single 
product in a quantitative manner, amplification efficiency and a correlation coefficient 
from a standard curve was determined for each gene using qRT-PCR (Figure 3.1).  
Purelink™ PCR Purification Kit (Invitrogen, K3100-01) was used to purify PCR products 
in order to individually optimize each transcript in the amplified calibrator cDNA.  A 
standard curve for each gene was generated from the purified PCR product at six 
different 10-fold dilutions. The calibrator cDNA was produced from a mixture of RNA 
from two BFF cell lines at four different passages that was reverse transcribed into 
cDNA using the same method previously described.  All of the target genes had 
acceptable efficiencies (80 to 120%) and correlation coefficients (close to 1.0). 
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RT-PCR followed by gel electrophoresis was first employed to confirm the 
presence of Oct-4, Nanog and Sox-2 transcripts in BFF cells treated with ADAS cell 
extracts.  Primer sets for Oct-4, Nanog, and the reference gene, polyadenylate 
polymerase (PAP), have previously been verified to amplify their respective transcripts 
in bovine embryos.  All primers were designed from bovine gene sequences using the 
Beacon Designer 4.0 (PREMIER Biosoft International) (Table 4.1), and were diluted to 
10 mM concentration. Reactions were carried out in a total volume of 25 µl, which 
consisted of 2.5 µl cDNA, 1 µl of each primer (sense and antisense), 12.5 µl of 
JumpStart™ REDTaq® ReadyMix™ PCR Reaction Mix (Sigma, No. P0982), and 8 µl of 
water.  The program used to amplify all genes in each sample involved a denaturating 
cycle of 1 min at 95˚C; 35 cycles of PCR (95˚C for 30 sec, 55˚C for 30 sec, and 72˚C for 
30 sec); 4 min at 72˚C; and a final holding temperature of 4˚C.  PCR products were 
electrophoresed on a 2% agarose gel and sequenced to confirm the correct products 
were amplified.  To assure that the primer sets not amplify genomic DNA, 1 ng of 
genomic DNA was used as a template for the amplification of the target genes.  No 
amplicons were recovered after RT-PCR of genomic DNA (data not shown). 
Quantitative Real-Time PCR 
The expression levels of Oct-4, Nanog and Sox-2 in BFF cells treated with ADAS 
cell extracts were quantified using The LightCycler® 480 Real-Time PCR System 
(Roche Applied Science, Indianapolis, IN, USA).  cDNA was amplified using SsoFast™ 
EvaGreen supermix (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The total 20 μl 


























PAP X63436 Sense AAGCAACTCCATCAACTACTG 
Antisense ACGGACTGGTCTTCATAGC 
169 
Table 4.1. Primers used for qRT-PCR analysis 
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6 μl of nuclease-free water, and 1 μl of forward and reverse primer pairs (10 mM) for 
each gene.  Within each qRT-PCR plate setup, reactions for the reference gene and 
each gene of interested were performed using the calibrator cDNA, the sample cDNA, 
and a no template negative control.  The PCR program used for the amplification of all 
genes consisted of a denaturing cycle of 30 sec at 95°C; 45 cycles of PCR (95°C for 5 
sec and 55°C for 20 sec); a melting curve analysis which consisted of 95°C for 5 sec, 
65°C for 1 min, followed by continuous acquisition at 97˚C, with 5 acquistions per ˚C; 
and a final holding temperature of 40°C. 
 Data was quantified using the method for relative quantification in qRT-PCR 
described by Pfaffl (2001).  Values are reported as relative transcription or the n-fold 
difference relative to a calibrator. A mixture of cDNA from BFF cells at multiple 
passages was used as a calibrator for all of the target genes.  PAP was 
used as the internal reference gene. The threshold cycle (Puissant et al.) value of the 
referencegene was used to normalize the target gene signals in each sample. The 
amount oftarget transcripts relative to the calibrator was calculated using the following 
equation: n-fold difference = Efficiency Target GeneΔCTT/ Efficiency Reference 
GeneΔCTR, where an efficiency value of two was assumed.  The ΔCTT (for the target 
gene) value was calculated by subtracting the sample CT value of the target gene from 
the calibrator CT value of the target gene. The ΔCTR (for the reference gene) value was 
calculated by subtracting the sample CT value of the reference gene PAP from the 
calibrator CT value of the reference gene. Therefore, all target abundance levels were 
expressed as n-fold differences relative to a calibrator and normalized to the reference 




 Data were analyzed using SigmaStat Statistical Software Version 3.5 (Systat 
Software, Richmond, CA, USA).  A T-test was performed to compare Oct-4, Nanog and 
Sox-2 expression levels between all untreated ADAS cell and BFF cell samples with 
BFF cells exposed to ADAS cell extracts and BFF cells exposed to hESC extracts.  
Differences of P < 0.05 were considered to be significant.   
 A 95% confidence interval for the gene expression levels for each gene of 
interest was formulated using descriptive statistics. If the n-fold difference relative to the 
calibrator for each treatment group equivalent did not fall within the confidence interval 
for the untreated group, they were considered abnormal, either upregulated or 
downregulated. 
Results 
 The extract-based nuclear reprogramming procedure was performed a total of 
nine times; however, only four of these times did BFF cells survive in culture following 
treatment.  Initially, we exposed permeabilized BFF cells to extracts that had previously 
been prepared and stored at -80˚C.  When we observed that none of these cells 
survived, we attributed it to instability of the extracts as a result of being stored at -80˚C 
for an extended period of time.  While Collas’s (www.collaslab.com) protocol for extract-
based reprogramming of somatic cells  states that extracts can be frozen and stored at  
-80˚C, it does recommend carrying out reprogramming reactions with freshly prepared 
extracts as the stability of extracts stored and frozen at -80˚C may vary with cell types 
and batches.  Based on this, we carried out all subsequent reprogramming reactions 
with freshly prepared extracts; however, this did not ensure cell survival following every 
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treatment.  Of the eight additional times we conducted the reprogramming experiment, 
only four times did the treated cells survive in culture.   
 The values corresponding to the relative expression of Oct-4, Nanog and Sox-2 
in all BFF cells exposed to ADAS cell extracts and hESC extracts are reported in tables 
4.2.and 4.3.  Statistical analysis comparing Oct-4, Nanog and Sox-2 expression levels 
in all untreated ADAS cells and BFF cell samples at all three passages with those of 
BFF cells exposed to ADAS cell extracts revealed no significant difference in Oct-4, 
Nanog and Sox-2 expression.  Comparisons between only untreated ADAS samples 
and BFF cells exposed to ADAS cell extracts also revealed no significant difference in 
Oct-4, Nanog and Sox-2 expression levels.  Interestingly, a significant difference in  
Sox-2 expression between untreated BFF cells and BFF cells exposed to ADAS cell 
extracts was found (P = 0.003); however, there was no significant difference in either 
Oct-4 or Nanog expression in these two groups (Table 4.4).   
 Statistical analysis comparing Oct-4, Nanog and Sox-2 transcript levels in all 
untreated ADAS cells and BFF cell samples at all three passages with those of BFF 
cells exposed to hESC extracts revealed no significant difference in Oct-4, Nanog and 
Sox-2 expression.  Likewise, no significant difference in Oct-4, Nanog and Sox-2 
expression was found when only untreated ADAS cell samples were compared to BFF 
cells exposed to hESC extracts and when only untreated BFF cell samples were 









Sample Oct-4 Nanog Sox-2 
BFF#1 w/ A (Rep 1) 5.90 0.24 0.60 
BFF#1 w/ A (Rep 2) 0.78 0.18 0.61 
BFF#1 w/ A (Rep 3) 0.84 0.19 0.32 
BFF#1 w/ B 1.40 2.43E-2 1.10 
BFF#1 w/ D 0.03 6.33 0.45 
BFF#2 w/ B 2.55E4 4.61E-2 1.13 
BFF#2 w/ C 0.05 23.09 0.23 







Table 4.2. Oct-4, Nanog and Sox-2 relative expression levels in BFF cells treated with 
ADAS cell extracts1   
1 BFF#1 and BFF#2 were treated with extracts derived from four ADAS cell lines, 










Sample Oct-4 Nanog Sox-2 
BFF#1 (Rep 1) 4.60E-3 3.81E-5 3.47E-4 
BFF#1 (Rep 2) 6.24E-3 4.14E-5 2.35E-4 
BFF#2 (Rep 1) 1.64E-2 4.97E-2 5.83E-3 
BFF#2 (Rep 2) 4.13 3.35 2.70 
BFF#2 (Rep 3) 5.04E-2 2.44E-3 3.20E-4 
BFF#2 (Rep 4) 9.94E-2 3.03E-3 1.56E-3 









BFF w/ ADAS extracts 
n=8 
Oct-4 0.39 3188.63 
Nanog 4.19 5.35 
Sox-2 0.03a 0.58a 
Table 4.4 Comparison of the mean Oct-4, Nanog and Sox-2 expression levels between 
untreated BFF cells and BFF cells treated with ADAS cell extracts  
Statistical differences were determined by t-test (P < 0.05) 








BFF w/ hESC extracts 
n=6 
Oct-4 0.39 0.72 
Nanog 4.19 0.57 
Sox-2 0.03 0.45 
Table 4.5 Comparison of the mean Oct-4, Nanog and Sox-2 expression levels between 
untreated BFF cells and BFF cells treated with hESC extracts  
Statistical differences were determined by t-test (P < 0.05) 




 The remarkable ability to give rise to all the cell types of the body not only defines 
the inherent nature of ESC, but also underlines their enormous potential as donor cells 
for cell transplantation therapies.  Despite the promise of ESC, ethical concerns and 
potential immune rejection after transplantation are current major hindrances of their 
use.  Reprogramming the nuclei of differentiated cells to an ESC-like state may be a 
solution to both of these problems.  Successful reprogramming of somatic cells towards 
pluripotency has been accomplished through SCNT (Wilmut et al., 1997), fusion with 
ESC (Cowan et al., 2005), ectopic expression of defined transcription factors 
(Takahashi and Yamanaka, 2006), and exposure to ESC extracts (Bru et al., 2008).  
Each of these methods has proven to facilitate the reacquisition of pluripotency in 
differentiated somatic cell nuclei, yet no technique is without its limitations.  
Nonetheless, these four different experimental strategies demonstrate that pluripotency 
can be restored in terminally differentiated cells, proving that the epigenetic state of 
somatic cells is not irreversibly fixed (Jaenisch and Young, 2008).   
In the present study, we detected the presence of Oct-4, Nanog and Sox-2 
transcripts in both bovine ADAS cells and BFF cells.  The presence of these central 
transcription factors characteristic of pluripotent stem cells suggests that these cells 
may possess characteristics similar to ESC, including epigenomic regulatory pattern.  
Therefore, ASC may be better equipped for complete epigenetic reprogramming than 
terminally differentiated cells.  Because the endogenous expression of Oct-4, Nanog 
and Sox-2 is believed to contribute towards reprogramming efficiency, we sought to 
increase their expression level in BFF cells through exposure to nuclear and 
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cytoplasmic extracts derived from ADAS cells.  Extract-based reprogramming 
approaches have shown that differentiated cells may be induced to transdifferentiate 
into other differentiated cell types (Collas and Håkelien, 2003) or dedifferentiate towards 
pluripotency (Taranger et al., 2005; Bru et al., 2008).  To our knowledge, this is the first 
report measuring Oct-4, Nanog and Sox-2 expression levels in ASC exposed to extracts 
of other ASC.   
The successful reprogramming of cells using the cell-extract based system has 
been reported by many groups  (Ha°kelien et al., 2002; Landsverk et al., 2002; Collas 
and Håkelien, 2003; Taranger et al., 2005; Freberg et al., 2007; Bru et al., 2008);  
however, we observed  a great deal of variability in cell survival between experiments.   
Such variability in the effectiveness of reprogramming attempts using cell extracts has 
also been observed by others (www.collaslab.com).  This variability may be due to 
differences in the relative reprogramming potential of ADAS cell extracts prepared, or 
the effectiveness of reversible permeabilization, which was not monitored all ten times 
the experiment was conducted.  Furthermore, cell extracts have been reported to 
manifest varying amounts of toxicity, with some extracts being completely ineffective for 
reprogramming (Ha°kelien et al., 2002).   
Even in the four “successful” experiments, we observed many dead cells in 
culture following treatment.  Fortunately, in these cases enough cells survived treatment 
to expand in culture, thus allowing mRNA to be isolated.  It should be noted that we only 
had to conduct the reprogramming experiment with hESC once, as the BFF survived 
exposure to these extracts.  While we cannot rule out that this is due merely to chance, 
it may be that extracts derived from hESC are less toxic to permeabilized cells than 
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extracts derived from somatic cells.  This is simply an observation, and validation of this 
hypothesis has not been reported.   
In other studies, successful reprogramming was marked by factors such as the 
nuclear uptake of transcription factors and cell surface antigens specific to the cell type 
from which the extracts were derived, chromatin remodeling activity, changes in gene 
expression patterns, and changes in morphology.  In most of these studies, the cell type 
being reprogrammed was much different than that of the cell type from which the 
reprogramming extracts were derived; therefore, factors such as gene induction were 
measurable.  Because Oct-4, Nanog and Sox-2 were found to be present in both BFF 
cells and ADAS cells, we could not assess induced expression of otherwise repressed 
genes.  Instead, we analyzed samples for changes in the expression pattern of these 
genes.  Unlike other studies that have reported the upregulation of Oct-4, Nanog and 
Sox-2 in cells treated with extracts derived from hESC (Taranger et al., 2005; Freberg et 
al., 2007) and murine ESC (Bru et al., 2008), our statistical analysis revealed no 
significant difference in Oct-4, Nanog and Sox-2 expression levels between untreated 
BFF cells and ADAS cells and BFF cells treated with hESC. One possible explanation 
for this may be due to expression differences between species.  Another explanation for 
this may be the use of reprogramming extracts derived from higher passage number 
ESC as opposed to very early passage number ESC.  The hESC we used to derive 
nuclear and cytoplasmic extracts had previously been cultured for an unknown number 
of passages before being frozen and then given to us for culture. Furthermore, after the 
initial plating on feeder layers of MEF, we passaged the hESC two additional times 
before deriving extracts from them.  Although we do not know the exact passage 
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number of the hESC when we received them, it is likely that by the time we obtained 
extracts from these cells they were at a high passage number.   
In the present study, we did not detect a significant difference in Oct-4 and 
Nanog transcript levels between untreated BFF cells and ADAS cells and BFF cells 
exposed to ADAS cell extracts.  However, a comparison between untreated BFF cells 
and BFF cells treated with ADAS cell extracts revealed a significant difference in Sox-2 
expression levels.  It should be noted that Sox-2 expression levels were not found to be  
significantly different between untreated ADAS cells and BFF cells treated with ADAS 
cell extracts.  This was also the case when we compared all untreated BFF cells and 
ADAS cells with BFF cells exposed to ADAS cell extracts.  It is surprising that Sox-2 
expression levels increased significantly following treatment, but Oct-4 and Nanog 
levels did not as it has been shown that the expression levels of these three 
transcriptional regulators are tightly linked (Boyer et al., 2005).  Other studies have 
reported similar findings, in which an increase in Oct-4 expression was not 
accompanied by an increase in Nanog expression following extract exposure (Neri et 
al., 2007).  The investigators in these studies also reported being surprised by their 
findings, and concluded that in these instances only partial reprogramming of the donor 
cell nucleus occurred.  It is possible that our findings are due to only the partial 
reprogramming of BFF nuclei following extract exposure.  Because Oct-4 and Nanog 
expression is repressed before Sox-2 during differentiation, it may be more difficult to 
reprogram Oct-4 and Nanog to a sufficient state.  However, further research is needed 
before a definitive conclusion can be made regarding the pattern of gene expression we 




SUMMARY AND CONCLUSIONS 
The extraordinary nature of ESC lends them the remarkable ability to give rise to 
all the cell types of a mammalian organism, an attribute known as pluripotency. The 
pluripotent state of ESC is dependent upon the expression of the genes Oct-4, Nanog 
and Sox-2, which have also been identified as the key transcriptional regulators of 
pluripotency (Boyer et al., 2005).  Until recently, Oct-4, Nanog and Sox-2 were believed 
to be expressed solely in ESC; however, studies have reported the expression of these 
genes in some sources of ASC of both the mouse and pig (Kues et al., 2005; Carlin et 
al., 2006).  Furthermore, these ASC as well as several other sources of ASC have been 
shown to exhibit a surprisingly high degree of plasticity.  This remarkable feature allows 
ASC to cross lineage barriers and adopt the expression profiles and functional 
phenotypes of cells unique to other tissues (Herzog et al., 2003).  These findings 
suggest that ASC possess characteristics similar to pluripotent ESC, including 
epigenetic regulatory pattern.  Considering the abundance and accessibility of adipose 
tissue, ADAS cells are an attractive source of stem cells for use in research and 
biomedical applications.   
 In the present study, we first examined cells derived from bovine adipose tissue 
as well as fetal fibroblasts for the expression of Oct-4, Nanog and Sox-2.  Transcripts 
for all three pluripotency-associated genes were detected in all BFF cell and ADAS cell 
samples at every passage analyzed.  It has been suggested that the genome of less 
differentiated cells may be more amenable to reprogramming or require less 
reprogramming following the induction of pluripotency either by SCNT or another 
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experimental strategy (Rideout et al., 2001).  Because of the high degree of plasticity 
demonstrated by ADAS cells, it is likely that these cells have an epigenomic regulatory 
pattern that is closer to pluripotent ESC than terminally differentiated somatic cells (Sun 
et al., 2009).  Although we found the Oct-4, Nanog and Sox-2 expression levels in 
ADAS cell samples to be quite low and highly variable between cell lines and passage 
numbers, their presence supports the notion that these cells are less differentiated than 
other somatic cells.   
Because the endogenous expression of Oct-4, Nanog and Sox-2 is believed to 
contribute to reprogramming efficiency, we next attempted to increase the expression 
levels of these genes by exposing BFF cells to ADAS cell extracts.  Extract-based 
reprogramming approaches have shown that differentiated cells may be induced to 
transdifferentiate into other differentiated cell types (Collas and Håkelien, 2003) or 
dedifferentiate towards pluripotency (Taranger et al., 2005; Bru et al., 2008).  Because 
the genome of ASC is inherently less differentiated than other somatic cells, exposing 
them to extracts of other ASC may drive them further towards an undifferentiated state.  
Extract-based reprogramming using ASC is a promising and plausible approach 
towards the production of replacement cells for therapeutic purposes, as well as, the 
production of suitable donor cells for SCNT.   
As with any technology, there is always room for improvement, and extract-
based reprogramming of somatic cells is no exception. The degree of variability in the 
effectiveness of reprogramming attempts using cell extracts is, in our opinion, this 
reprogramming strategy’s greatest hindrance.  Furthermore, the application of this 
technology to produce replacement cells for therapeutic purposes requires significant 
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developments and a large body of data is needed before this system can be applied to 
the generation of cells used for therapy in human patients (Collas and Håkelien, 2003).  
We believed that the high variability in Oct-4, Nanog and Sox-2 expression we observed 
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APPENDIX A: PROTOCOLS 
ADAS AND BFF CELL ISOLATION PROTOCOL 
1. Collect adipose tissue from each specimen and place in the wash solution.  Maintain 
samples on ice 
2. Under a hood, transfer tissue to a weighing boat and mince the tissue 
3. Transfer minced tissue to a 50 ml conical tube and add 25 ml of wash solution 
4. Shake tube vigorously for 30 sec and allow phases to separate (about 5 min) 
5. Carefully aspirate solution so not to remove any of the sample 
6. Repeat wash, shake, and aspiration 
7. Pour sample into a 150 ml Erlenmeyer flask.  (if sample does  not easily pour into 
the flask, remove using sterile forceps) 
8. Add approximately 15-20 ml of .25% collagenase solution (.25% collagenase + 1% 
BSA (Fraction V + PBS with Ca+2 and Mg+2) 
9. Add 200 µL of P/S and 200 µL of Fungizone to the flask containing tissue and 
collagenase solution 
10. Cover flask with parafilm and place in shake incubator set at 200 rpm at 37˚C for 2 h 
11. After incubation, transfer entire suspension to a new 50 mL tube 
12. Centrifuge 300 x g for 5 min 
13. Following centrifugation, shake tubes vigorously for 15 to 30 sec  
14. Repeat centrifugation 
15. Remove tissue from flask, leaving liquid in the tube and shake  
16. Pour contents into a double filter syringe system with a new 50 ml tube receiving the 
filtered solution  
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17. Centrifuge 300 x g for 5 min  
18. Aspirate collagenase solution 
19. Resuspend pellet in 15 ml of PBS with Ca+2 and Mg+2 + 1% BSA (Fraction V) 
20. Centrifuge 300 x g for 5 min 
21. Aspirate supernatant 
22. Add approximately 10 ml of DMEM + 10% FBS + 1% P/S + 2% Fungizone 
23. Centrifuge 300 x g for 5 min 
24. Aspirate supernatant  
25. Resuspend cell pellet in 1 ml of complete culture media (BFF cells: DMEM with 15% 
FBS + 1% P/S; ADAS cells: DMEM with 10% FBS + 1% P/S) and plate in 
appropriate size flask 
26. Add appropriate amount of complete culture media to flask and place in incubator 















TRI REAGENT® RNA ISOLATION PROTOCOL 
1. Remove media from culture dish 
2. Add 1 ml of TRI Reagent® per 10cm2 to culture dish and pipette up and down 
several times 
3. Incubate homogenate at room temperature for 5 min 
4. While homogenate is incubating, prep phase lock tubes by centrifuging 3500 x g 
for 10 min at 4˚C. 
5. Transfer TRI Reagent® cell suspension to Phase-Lock Gel tube 
6. Add 0.1 ml of BCP per 1 ml of TRI Reagent used to suspension 
7. Secure caps and shake vigorously for 30 sec 
8. Incubate tube at room temperature for 1 h 
9. After incubation period, centrifuge at 12,000 x g for 15 min at 4˚C.     
10. Transfer the clear aqueous supernatant to a fresh 15 ml tube 
11.   Precipitate RNA by adding 0.5 ml of isopropyl alcohol per 1 ml of TRI Reagent® 
used in initial homogenization to aqueous supernatant.   
12.   Store overnight at -20˚C for optimum recovery of RNA 
13.   Centrifuge at 12000 x g for 20 min at 4˚C.  The RNA will form a small gel-like or 
white pellet. 
14.   Pour off supernatant away from the pellet 
15.   Centrifuge pellet at 12000 x g for 2 min at 4˚C 
16.   Wash the RNA pellet in 75% EtOH (prepared in DEPC water) using at least      
1 ml of EtOH per 1mL of TRI Reagent® 
17.   Vortex tube until pellet is floating 
18.   Centrifuge 14000 x g for 10 min 
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19.   Carefully transfer the RNA pellet to a 1.5 ml tube containing 1 ml of 75% EtOH 
20.   Repeat centrifugation 
21.   Remove supernatant and allow pellet to dry under a laminar flow hood 

















DYNABEADS® RNA ISOLATION PROTOCOL 
1. Harvest cells from culture flask as per standard procedure 
2. Wash cell pellet first in 1 ml of PBS with Ca+2 and Mg+2  and then in 300 µl of 
lysis/binding buffer (100mM Tris HCl (pH 8.0), 500 mM LiCl, 10 mM EDTA, 1% 
lithium dodecylsulfate, and 5 mM dithiothreitol) 
3. Strip cells using a 21 gauge needle and a 1 ml syringe.  Vortex for 10 sec. 
4. Centrifuge at 12000 x g for 15 sec. and incubate at RT for 10 min. 
5. Add 50 µl of the pre-washed oligo dT Dynabeads (dT25) to the tube (pre-washed 
Dynabeads in lysis/binding buffer) 
6. Incubate at RT for 10 min in hybridization mixer 
7. Place tube in magnetic separator for 2 min 
8. Remove supernatant and wash beads twice in 50 µl of Buffer A (10 mM Tris HCl 
(pH 8.0), 150 mM LiCl, 1 mM EDTA, 0.1% lithium dodecylsulfate) and twice in  
50 µl of Buffer B (10 mM Tris HCl (pH 8.0), 150 mM LiCl, 1 mM EDTA). 
9. Elute RNA from the beads by adding 15µL of nuclease-free water and heating 
the sample at 70˚C for 2 min. 







cDNA SYNTHESIS PROTOCOL 
1. Mix 4 µl of iScript reaction mix, 1 µl of reverse transcriptase, and 15 µl of sample 
mRNA in PCR tube (Bio-Rad Laboratories, Inc., Hercules, CA, USA)  
2. Place tubes in the thermocycler and run for 5 min at 25˚C, 30 min at 42˚C, 

















1. Each reaction is carried out in a total of 25 µl.  Mix 12.5µL of JumpStart™ 
REDTaq® ReadyMix™ PCR Reaction Mix (Sigma, No. P0982), 8 µl of water,      
1 µl of each [10mM] primer (sense and antisense), and 2.5 µl of sample cDNA.  
Prepare master mixes whenever possible. 
2. Place tubes in thermocycler and run a denaturating cycle of 1 min at 95˚C; 35 
cycles of PCR (95˚C for 30 sec, 55˚C for 30 sec, and 72˚C for 30 sec); 4 min at 
72˚C; and a final holding temperature of 4˚C. 
3. Upon completion, remove samples from the thermocycler and add 12.5 µl of 













1. Prepare master mixes for each gene being analyzed (Oct-4, Nanog, Sox-2, 
PAP).  Each reaction contains 10 µl of SsoFast™ EvaGreen supermix (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA), 6 µl of nuclease-free water, 1 ul of each 
[10 mM] primer (sense and antisense), and 2 µl of either sample or calibrator 
cDNA (added later).   
2. Pipette 18 µl of the appropriate master mix into the designated wells of a 96 
multiwell plate tailor-made for LightCycler® 480 Instrument (Roche No. 
04729692001).   
3. Add 2 µl of either sample or calibrator cDNA to each designated well 
4. Cover plate with sealing foil 
5. Place plate in the LightCycler® 480 Instrument and run a denaturing cycle of 30 
sec at 95°C; 45 cycles of PCR (95°C for 5 sec and 55°C for 20 sec); a melting 
curve analysis which consisted of 95°C for 5 sec, 65°C for 1 min, followed by 
continuous acquisition at 97˚C, with 5 acquistions per ˚C; and a final holding 










REPROGRAMMING SOMATIC CELLS IN CELL-FREE EXTRACTS PROTOCOL 
Derivation of Extracts 
1. Remove cells from culture and remove media 
2. Wash with PBS without Ca+2 and Mg+2 and remove 
3. Add appropriate amount of Trypsin to flask (.5 ml for T-25) 
4. Place in 37˚C oven for about 5 min 
5. Add approximately 5 ml of complete culture medium and move to 15 ml 
tube 
6. Centrifuge at 300 x g for 10 min at 4˚C 
7. Remove remaining media 
8. Wash cells in 10 ml of ice cold PBS with Ca+2 and Mg+ 2and centrifuge at 
300 x g for 10 min at 4˚C.  Discard supernatant. 
9. Repeat 
10. Remove 500 µl of Cell Lysis Buffer (without Protease Inhibitor Cocktail) 
and set aside.  Resuspend cells in remaining  ice-cold Cell Lysis Buffer 
(without Protease Inhibitor Cocktail) 
11. Centrifuge at 300 x g for 10 min at 4˚C.  Discard supernatant. 
12. Add 10 µl of Protease Inhibitor Cocktail and 5 µl of EDTA to the 500 µl of 
Cell Lysis Buffer. 
13.  Estimate cell pellet volume, and resuspend cells in 1 volume of Cell Lysis 
Buffer containing the Protease Inhibitor Cocktail and EDTA. For cells 
grown in T-12.5, add 250 µl of the 500 µl solution of Cell Lysis Buffer.  
Adjust as needed. 
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14. Transfer the cell suspensions to individual 1.5 ml tubes   
15. Place tubes on ice for 30-45 min., tapping the tubes occasionally to keep 
cells suspended.   
16. Remove cell suspension from each tube and move to pestle for Dounce 
Homogenization.  Lyse cells on ice using the mortar and pestle.  Monitor 
cell lysis progress using microscopy, and continue Dounce 
Homogenization until 90% of cells lysed.   
17. Move cell lysate to pre-chilled 1.5 ml tubes.  Make sure to get the liquid off 
of the sides and top of mortar and pestle.   
18. Centrifuge these tubes containing cell lysate at 15,000 x g for 15 min at 
4˚C. 
19. Carefully collect the supernatant from the tubes using a 200 µl pipette and 
transfer to a new pre-chilled 1.5 ml tube.  The supernatant contains the 
extract and the pellet is discarded.   
20. Resuspend the remaining extract using a 200 µl pipette and then aliquot 
100 µl of extract into 1.5 ml tubes on ice.  
21. At this point, extracts can be flash frozen using liquid N2 and stored in -
80˚C till use; however, it is best to carry out reprogramming reactions with 
fresh extracts.  
Permeabilization of Donor Cells 
1. Remove aliquots of SLO in 10mM DTT from -20˚C.  (SLO powder 




2. Dilute SLO stock in PBS without Ca+2 and Mg+2 in a 1:20 ratio.  (The 
appropriate ratio for the given cell type indicates the proper concentration 
of SLO needed to cause 70-80% permeabilization).  This is your “SLO 
working solution”. 
3. Keep “SLO working solution” on ice.  
4. In the interim, remove media from “donor cells” 
5. Wash cells in PBS without Ca+2 and Mg+2 and remove 
6. Add appropriate amount of Trypsin to flask (.5 ml for T-25) 
7. Place in 37˚C oven for about 5 min 
8. Add approximately 5mL of complete culture medium and move to 15mL 
tube 
9. Centrifuge at 300 x g for 10 min at 4˚C 
10. Remove remaining media 
11. Wash cells in ice-cold PBS without Ca+2 and Mg+2 and centrifuge at      
400 x g for 10 min at 4˚C.  Discard supernatant and repeat this two more 
time.  It is essential to remove all of the Ca+2 because it inhibits SLO 
activity. 
12. After first wash in PBS without Ca+2 and Mg+2, remove 10 µl of cell 
suspension and add to 90 µl of complete culture medium.  Count cells.   
13. When final centrifugation is complete, remove supernatant and resuspend 
cell pellet in 1 ml of PBS without Ca+2 and Mg+2 and aliquot desired 
number of cells (100,000) into 1.5 ml pre-chilled tubes.   
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14. Centrifuge these tubes at 300 x g for 5 min at 4˚C.  Discard the 
supernatant.  
15. Carefully resuspend the cell pellet in 488µL of ice-cold PBS without Ca+2 
and Mg+2 using a 1000 µl pipette with a  large tip. 
16. Place the tubes in 37˚C water bath for 2 min and then add 12 µl of “SLO 
working solution”.  Mix by tapping on the tube.   
17. Remove the tubes from the water bath and incubate horizontally at 37˚C 
for 50 min.  Tap occasionally on the tubes to maintain cell suspension.  
18. After incubation, place tubes on ice and add 500 µl of ice-cold PBS 
without Ca+2 and Mg+2 
19. Centrifuge the tubes at 300 x g for 5 min at 4˚C.  Remove supernatant 
before in vitro reprogramming.   
Cell Permeabilization Assay 
1. Harvest donor cells as per standard protocol (see above) 
2. Discard remaining media following centrifugation, and wash cell pellet in 
ice-cold PBS with Ca+2 and Mg+2 
3. Centrifuge at 300 x g for 10 min at 4°C 
4. Discard supernatant and repeat wash step two more times.  Do not 
discard supernatant after final spin. 
5. Determine the number of cells you want to use (Collas suggests 500,000) 
and resuspend the cell pellet in the remaining PBS without Ca+2 and Mg+2 
Aliquot desired number of cells into 1.5 ml tubes on ice 
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6. Centrifuge the 1.5 ml tubes at 300 x g for 5 min at 4°C.  Discard 
supernatant.  
7. Resuspend cell pellet in 488 µl of PBS without Ca+2 and Mg+2 that contains 
approximately 5 µl of Propidium Iodide 
8. Place tubes in 37°C water bath for 2 min to allow cells to heat up 
9. Next, add 12 µl of the ice-cold SLO working solution to each tube and mix 
by gentle pipetting  
10. Incubate the tubes at 37°C for 50 min, tapping cells occasionally 
11. Following incubation, centrifuge cells at 300 x g for 5 min at 4°C 
12. Discard supernatant 
13. Add 1.5 ml of complete culture medium, containing 2 mM of CaCl2 to each 
tube 
14. After a few minutes, observe cells under fluorescent microscopy to 
determine if permeabilization occurs and the cells took up the P.I. If the 
cells glow red, they took up P.I.  P.I. stains DNA, so it is best to see the 
red concentrated in the nucleus.  Calculate the percentage of cells that 
took up P.I. to determine the proper concentration of SLO.   Optimal SLO 
concentration is indicated by approximately 70-80% of cells being 
permeabilized.   
In Vitro Reprogramming 




2. If extracts were not previously aliquoted, aliquot 100 µl of extracts into   
1.5 ml tubes and hold on ice.  If extracts were frozen, promptly thaw the 
extract between fingers and place on ice.   
3. Add 5 µl of ATP-Regenerating System to 100 µl of extracts (adjust 
accordingly) and mix by gentle pipetting  
4. Add extract and ATP-Regenerating System mix to tube of permeabilized 
cells.  (For 100,000 cells, add 100µL of the mix.  Adjust accordingly).  
Carefully suspend with 1000 µl pipette tip 
5. Incubate cells horizontally in 37°C water bath for 1 h, tapping tubes 
occasionally.   
6. At the end of the incubation, add 1 ml of complete culture medium 
containing 2 mM CaCl2 added from 1 M stock to reseal the cell membrane. 
7. Plate the contents of each tube and culture for 2 to 4 hours in 5% CO2 
incubator at 37°C (for 100,000 cells, plate in individual wells of 24-well 
plate).   
8. After culture period, remove the dead cells (floating) and the CaCl2 –
containing media.  Replace with the complete culture medium (without 
CaCl2) that the cells are now being cultured in  




















Component Product Number Company Amount 
100 mM HEPES H3375 Sigma 1 ml (1 M) 
50 mM NaCl S5886 Sigma 1 ml (500 mM) 
5 mM MgCl2 M2393 Sigma 1 ml (50 mM) 
0.1 mM Phenylmethysufonyl 
fluoride (PMSF) 
 
P7626 Sigma 100 µl (10 mM) 
1 mM Dithiothreitol (DTT) D9779 Sigma 1 mM 
Protease Inhibitor Cocktail 
(100X) 
P2714 Sigma 
10 µl per 500 µl 
of CLB 
 
0.5 M EDTA E5134 Sigma 
5 µl per 500 µl 
of CLB 
 
Cell Lysis Buffer1 
1 Primary stocks of 1M HEPES, 500mM NaCl, 50mM MgCl2 and 10mM PMSF were 
prepared and aliquots corresponding to their final concentration in the cell lysis buffer 
were made.  For 1mM DTT, 1.54mg of DTT powder was added directly to HEPES, 
NaCl, MgCl2 and PMSF, and the solution was brought up to 10 ml with sterile water.  
10 µl of 100X Protease Inhibitor Cocktail and 5 µl of EDTA was added to a 500 µl 

















Component Product Number Company Amount 












10 mM Guanosine 
5’-triphosphate 
























2 Primary stocks of 100 mM ATP, 10 mM GTP, 1 M Phosphocreatine and 2.5 mg/ml 
Creatine Kinase were prepared, aliquoted and stored at -20˚ C.  The  ATP-
Regenerating System Mix was prepared fresh by mixing  ATP,  GTP, 
Phosphocreatine and Creatine Kinase in a 1:1:1:1 ratio from each separate stock.  
For every 100 µl of extract, a total of 3 µl of ATP-Regenerating System Mix was 
supplemented.   





 Laura Whitney Coley was born on March 11, 1985 to Howard and Ann Coley in 
Texarkana, Texas.  In 2003, she graduated from Arkansas High School in Texarkana, 
Arkansas.   
Following high school, Laura moved to Baton Rouge, Louisiana to pursue a 
Bachelor of Science degree in animal, dairy and poultry sciences from Louisiana State 
University.  During her undergraduate studies, Laura became interested in reproductive 
physiology, and in her senior year, she participated in an undergraduate research 
project under the supervision of Dr. Kenneth R. Bondioli and Dr. Robert A. Godke. 
Laura entered the graduate program in reproductive physiology under the 
direction of Dr. Kenneth R. Bondioi in the fall of 2008 and is now a candidate for the 
degree of Master of Science in reproductive physiology in the Department of Animal 
Sciences at Louisiana State University, Baton Rouge, Louisiana. 
